

 Open access • Posted Content • DOI:10.1101/2020.05.20.087379

In vivo CRISPR screening identifies Fli1 as a transcriptional safeguard that restrains effector CD8 T cell differentiation during infection and cancer — [Source link](#)

Zeyu Chen, Eri Arai, Omar Khan, Zhen Zhang ...+22 more authors

Institutions: University of Pennsylvania, Johns Hopkins University, Kanazawa University

Published on: 20 May 2020 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: T cell, Cytotoxic T cell, Cellular differentiation and Effector

Related papers:

- [In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer.](#)
- [Chromatin accessibility of CD8 T cell differentiation and metabolic regulation.](#)
- [The IRF4 Gene Regulatory Module Functions as a Read-Write Integrator to Dynamically Coordinate T Helper Cell Fate](#)
- [Differential regulation of activation and differentiation processes in CD4+ T cell populations and their single-cell level heterogeneity](#)
- [The Transcription Factor Runx3 Establishes Chromatin Accessibility of cis-Regulatory Landscapes that Drive Memory Cytotoxic T Lymphocyte Formation.](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/in-vivo-crispr-screening-identifies-fli1-as-a-4wse8fyp08>

***In vivo* CRISPR screening identifies Fli1 as a transcriptional safeguard that restrains effector CD8 T cell differentiation during infection and cancer.**

Zeyu Chen^{1,2,3,6}, Eri Arai^{3,4}, Omar Khan^{1,2,9}, Zhen Zhang^{4,5}, Shin Foong Ngiow^{1,2,6}, Yuan He⁷, Hua Huang^{1,2,4,5}, Sasikanth Manne^{1,2}, Zhendong Cao^{3,4}, Amy E. Baxter^{1,2}, Zhangying Cai^{1,2}, Elizabeth Freilich³, Mohammed A. Ali^{1,2}, Josephine R. Giles^{1,2}, Jennifer E. Wu^{1,2}, Allison R. Greenplate^{1,2}, Makoto Kurachi^{1,2,10}, Kito Nzingha^{1,2}, Viktoriya Ekshyyan^{1,2}, Zhuoyu Wen³, Nancy A. Speck⁵, Alexis Battle^{7,8}, Shelley L. Berger^{4,5}, E. John Wherry^{1,2,6,*,#}, and Junwei Shi^{2,3,4,*}

¹Department of Systems Pharmacology and Translational Therapeutics, ²Institute for Immunology, ³Department of Cancer Biology, ⁴Epigenetics Institute, ⁵Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

⁶Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA

⁷Department of Biomedical Engineering, ⁸Department of Computer Science, Johns Hopkins University, Baltimore, MD, USA

⁹Present Address, Arsenal Biosciences, South San Francisco, CA, USA

¹⁰Present Address, Department of Biochemistry I, Graduate School of Medical Sciences, Kanazawa University, Japan

*Co-responding Authors

#Lead Contact: E.J.W. wherry@pennmedicine.upenn.edu

Summary

Improving effector activity of antigen specific T cells is a major goal in cancer immunotherapy. Despite the identification of several effector T cell (T_{EFF})-driving transcription factors (TF), the transcriptional coordination of T_{EFF} biology remains poorly understood. We developed an *in vivo* T cell CRISPR screening platform and identified a novel mechanism restraining T_{EFF} biology through the ETS family TF, Fli1. Genetic deletion of Fli1 enhanced T_{EFF} responses without compromising memory or exhaustion precursors. Fli1 restrained T_{EFF} lineage differentiation by binding to *cis*-regulatory elements of effector-associated genes. Loss of Fli1 increased chromatin accessibility at ETS:RUNX motifs allowing more efficient Runx3-driven T_{EFF} biology. CD8 T cells lacking Fli1 provided substantially better protection against multiple infections and tumors. These data indicate that Fli1 safeguards the developing CD8 T cell transcriptional landscape from excessive ETS:RUNX-driven T_{EFF} cell differentiation. Moreover, genetic deletion of Fli1 improves T_{EFF} differentiation and protective immunity in infections and cancer.

Introduction

Effective CD8 T cell (T_{EFF}) responses are important for control of chronic infections and cancer. Understanding the mechanisms that regulate T_{EFF} cell differentiation is therefore crucial to improving therapeutic approaches for cancer and other diseases. Activation of naïve CD8 T cells (T_N) during acutely resolved infections or following vaccination results in acquisition of new properties and differentiation into T_{EFF} cells accompanied by dramatic transcriptional and epigenetic remodeling. After antigen clearance, a more terminally differentiated subset of T_{EFF} cells gradually dies off over the ensuing days to weeks, while a small proportion of memory precursors (T_{MP}) further differentiates and seeds the long-term memory CD8 T cell (T_{MEM}) pool (Kaech and Cui, 2012). During chronic infections and cancer, however, differentiation of responding CD8 T cells is diverted down a path of exhaustion. Under these conditions, T_{EFF} cells become over-stimulated and persist poorly (Angelosanto et al., 2012; Chen et al., 2019b; Khan et al., 2019), whereas a population of activated precursors differentiate into exhausted CD8 T cells (T_{EX}) (Chen et al., 2019b; McLane et al., 2019). T_{EX} cells have high expression of multiple inhibitory receptors including PD-1, decreased effector functions compared to T_{EFF} cells, altered homeostatic regulation compared to T_{MEM} cells, and a distinct transcriptional and epigenetic program (Wherry and Kurachi, 2015). Blocking inhibitory receptor pathways like PD-1:PD-L1 can reinvigorate T_{EX} temporarily, restoring proliferative expansion and some effector-like properties (Barber et al., 2006; Huang et al., 2017; Pauken et al., 2016). Such checkpoint blockade has revolutionized cancer treatment, with clinical benefit demonstrated across multiple cancer types (Topalian et al., 2015). Despite of the success of checkpoint blockade, however, most patients do not achieve durable clinical benefit (Sun et al., 2018) and there is a great need to improve the efficacy of these immunotherapies by augmenting T cell differentiation and effector-like activity following checkpoint blockade or during cellular therapies.

There has been considerable interest in defining the populations of T cells responding to checkpoint blockade (Ribas and Wolchok, 2018; Wei et al., 2018) and interrogating the optimal differentiation states for cellular therapies such as CAR T cells (Brown and Mackall, 2019). T_{EX} cells are prominent in human tumors and likely represent a major source of tumor reactive T cells (Duhon et al., 2018; Huang et al., 2017; Simoni et al., 2018). PD-1 pathway blockade mediates clinical benefit, at least in part, due to reinvigoration of T_{EX} cells allowing these cells to re-access parts of the T_{EFF} cell program (Huang et al., 2017; 2019; Pauken et al., 2016). However, limited therapeutic efficacy in many patients is associated with either suboptimal reinvigoration of T_{EX} cells or failure to achieve durable changes in T_{EX} differentiation state (Huang et al., 2017; 2019; Koyama et al., 2016). A key subset of T_{EX} cells required for the therapeutic benefit of PD-1 blockade in mouse models is a progenitor population of T_{EX} cells that, upon PD-1 blockade differentiates into a more numerous terminally exhausted subset (Blackburn et al., 2008). This progenitor subset retains some proliferative capacity, expresses the transcription factor TCF-1 and can be found in both mice (He et al., 2016; Im et al., 2016; Miller et al., 2019;

Utzschneider et al., 2016; Wu et al., 2016) and humans (Huang et al., 2019; Sade-Feldman et al., 2018). For cellular therapies, there is evidence that therapeutic failures are associated with the development of exhaustion (Chen et al., 2019a; Fraietta et al., 2018) and approaches that antagonize exhaustion are actively being investigated for CAR T cells (Long et al., 2015; Lynn et al., 2019; Wei et al., 2019). Moreover, cellular therapy products that are more stem T_{MEM} -like have improved efficacy (Alizadeh et al., 2019; Sommermeyer et al., 2016). However, a key to both response to checkpoint blockade and cellular therapies to control cancer is the ability to effectively engage a robust effector program, including numerical expansion and elicitation of effector activity. Understanding the underlying molecular mechanisms that control this effector activity is needed to effectively design therapeutic interventions for chronic infections and cancer.

The role of transcription factors (TFs) in regulating gene expression and differentiation of T_{EFF} versus T_{MEM} or T_{EX} has received considerable recent attention (Kaech and Cui, 2012; Wherry and Kurachi, 2015). For example TFs including Batf and Irf4 (Kurachi et al., 2014; Man et al., 2013), T-bet (Intlekofer et al., 2005; Joshi et al., 2007; Kao et al., 2011; Paley et al., 2012; Sullivan et al., 2003), Eomes (Intlekofer et al., 2005; McLane et al., 2013; Paley et al., 2012; Pearce et al., 2003; Zhou et al., 2010), Blimp-1 (Kallies et al., 2009; Rutishauser et al., 2009; Shin et al., 2009; Xin et al., 2016), Id-2 (Cannarile et al., 2006; Omilusik et al., 2018; Yang et al., 2011) and others (Kaech and Cui, 2012; McLane et al., 2019) drive T_{EFF} cell differentiation in acute and chronic infections. Batf and Irf4 have an early role in T cell activation and also induce the second wave of transcriptional induction of effector genes (Kurachi et al., 2014; Man et al., 2013). Runx3 induces T_{EFF} gene expression through T-bet and Eomes (Cruz-Guilloty et al., 2009) and also has a role in the early stages of differentiation of tissue resident memory CD8 T cells (T_{RM}) (Milner et al., 2017). Most T_{EFF} -associated genes and their cognate *cis*-regulatory regions are inaccessible to these TFs in the T_N state, therefore, the role of effector-driving TFs must be linked to chromatin accessibility changes that occur during the T_N to T_{EFF} transition. Indeed, there is emerging evidence that some of these early operating TFs, such as Batf, may contribute to T_{EFF} gene accessibility through chromatin remodeling (Pham et al., 2019).

In addition to TF that foster T_{EFF} formation, opposing mechanisms must temper complete commitment to effector differentiation. The two alternate cell fates, T_{MEM} and T_{EX} , cannot form from fully committed T_{EFF} (Angelosanto et al., 2012; Chen et al., 2019b; Joshi et al., 2007), suggesting that parts of the T_{EFF} program must be antagonized to allow T_{MEM} and T_{EX} to differentiate. The high mobility group (HMG) TF, TCF-1, for example, is essential for development and maintenance of both T_{MEM} and T_{EX} (Chen et al., 2019b; Im et al., 2016; Utzschneider et al., 2016; Wu et al., 2016; Zhou et al., 2010) TCF-1 represses (directly or indirectly) T_{EFF} -driving TF such as T-bet and Blimp-1 (Tiemessen et al., 2014), and may also have a role in enabling epigenetic changes (Xing et al., 2016). Moreover, a second HMG TF, Tox, is essential for the development of the T_{EX} cell fate by promoting T_{EX} differentiation and repressing of the T_{EFF} lineage differentiation (Alfei et al., 2019; Khan et

al., 2019; Scott et al., 2019; Seo et al., 2019; Yao et al., 2019). Tox reprograms the open chromatin landscape, inducing global T_{EX} -specific epigenetic changes and repressing chromatin accessibility associated with T_{EFF} differentiation, in part by recruiting epigenetic modifiers including the lysine acetyltransferase Kat7 (Khan et al., 2019). Despite this work, mechanisms that safeguard against commitment to T_{EFF} differentiation remain poorly understood. Such information could be of considerable utility for immunotherapies focused on enhancing anti-tumor or antiviral activity. However, whereas inactivating pathways like TCF-1 or Tox that would de-repress the entire program of T_{EFF} differentiation are of interest, such approaches result in terminal T_{EFF} and may have limited therapeutic benefit because such cells cannot sustain durable responses. Thus, the discovery of mechanisms that selectively de-repress key aspects of T_{EFF} differentiation, particularly those involved in control of numerical expansion and/or protective immunity would be of considerable interest.

Here, we used *in vivo* CRISPR-Cas9 screening in antigen-specific CD8 T cells responding to acute or chronic viral infection to identify key regulators of T_{EFF} and T_{EX} . In particular, we were interested in identifying genes that resulted by gain-of-function, improving T_{EFF} differentiation (i.e. an “Up” screen (Kaelin, 2017)). The CRISPR-Cas9 system has been used to interrogate the cancer-immune system through screening in cancer cells (Gerlach et al., 2016; Ishizuka et al., 2019; Manguso et al., 2017; Pan et al., 2018; Wang et al., 2019), *in vitro* in human T cells (Shifrut et al., 2018) or *in vivo* in mouse T cells (Dong et al., 2019; LaFleur et al., 2019b; Shifrut et al., 2018; Wei et al., 2019; Ye et al., 2019). Genome-wide or large pooled screens have identified regulators of T cell responses such as *Dhx37*, a dead-box helicase (Dong et al., 2019) and the phosphatase *Ptpn2* (LaFleur et al., 2019b; 2019a). More focused screens for metabolic regulators or membrane proteins have also identified targets such as *Zc3h12a* (encoding REGNASE-1) (Wei et al., 2019) and *Pdia3*, *Mgat5*, *Emp1* and *Lag3* (Ye et al., 2019). Many of these targets appear to function by modulating the activity state of the cell through altered signaling or RNA biology. For example, REGNASE-1 is a zinc finger protein that also may regulate mRNA decay (Uehata et al., 2013) and was implicated to function in CD8 T cells through regulation of BATF (Wei et al., 2019). Because Batf has a role in early transcription control of T_{EFF} differentiation, these findings suggest that *in vivo* CRISPR screening could potentially reveal key regulators of differentiation and developmental fate choices. However, the ability to discover fundamental regulators of cellular differentiation state and/or cellular programming via *in vivo* CRISPR/Cas9 screening in CD8 T cells relevant for immunotherapy remains a key goal. Thus, we developed an *in vivo* CRISPR-Cas9 screening platform in primary CD8 T cells focused on central regulators of T cell differentiation and fate decisions. This CD8 T cell CRISPR screening platform used Cas9⁺ antigen specific CD8 T cells combined with an optimized retroviral (RV) based-sgRNA expression strategy (named Optimized T cell In vivo CRISPR Screening system, OpTICS). We focused our screens on TF to identify genes with central regulatory roles in fate decisions and differentiation trajectories in T_{EFF} versus T_{EX} differentiation. Initially, we used the well-established LCMV infection system, in which the biology of T_{EFF} and T_{EX} can be interrogated with high precision, and then extended the findings to

other infection and tumor models. This approach identified known key TFs that are essential for T_{EFF} and T_{EX} differentiation including *Batf*, *Irf4* and *Myc* where loss of function prevented initial T cell activation and differentiation. We identified known TF that repress or restrain T_{EFF} differentiation including *Tcf7*, *Smad2* and *Tox*. However, this screen also revealed novel central regulators of T_{EFF} differentiation including many that repress optimal differentiation, such as *Irf2*, *Erg* and *Fli1*, where CRISPR perturbation led to gain-of-function and improved T_{EFF} responses. In particular, we discovered a novel central role for Fli1 in T_{EFF} responses where this TF specifically antagonized the genome-wide function of ETS:RUNX activity and prevented Runx3-driven T_{EFF} biology. Indeed, genetic loss of Fli1 resulted in robustly improved T_{EFF} responses whereas enforced Fli1 expression restrained differentiation. Fli1 prevented chromatin accessibility specifically at ETS:RUNX motifs and loss of Fli1 enabled transcriptional induction of the T_{EFF} program in a Runx3-driven manner. Moreover, loss of Fli1 improved T_{EFF} biology and protective immunity not only during LCMV infection, but also following infection with influenza virus or *Listeria monocytogenes*. Moreover, deletion of Fli1 potently improved anti-tumor immunity. Thus, Fli1 safeguards the developing activated CD8 T cell epigenome from excessive ETS:RUNX-driven T_{EFF} differentiation and disruption of Fli1 activity can be exploited to improve T_{EFF} activity and protective immunity to infections and cancer.

Results

Optimized CRISPR-Cas9 for gene editing in murine primary T *in vivo*.

Recently, several CRISPR-Cas9-based genetic perturbation approaches have been developed for unbiased genetic screen to reveal novel regulatory pathways in murine primary T cells *in vivo* (Dong et al., 2019; LaFleur et al., 2019b; Wei et al., 2019; Ye et al., 2019). The current methods either adoptive transferring the Cas9-edited bone marrow progenitors into recipient mice which could lead to unexpected developmental effects (LaFleur et al., 2019b) or using genome-wide screening approaches that require large, non-physiological numbers of CD8 T cells *in vivo* (Dong et al., 2019; Ye et al., 2019) which could skew responses to chronic infections and tumors with aberrant effects on disease control and T cell differentiation (Badovinac et al., 2007; 2004; Blackburn et al., 2008; Blattman et al., 2009; Marzo et al., 2005; Wherry et al., 2005). To address these limitations, we set out to develop a system that can 1) perform genetic manipulation in mature CD8 T cells and 2) use a physiological number of cells that mimicking normal T cell development in the setting of viral infections and cancer. To enable gene editing in antigen specific primary CD8 T cells, we crossed LSL-Cas9⁺ mice (Platt et al., 2014) to CD4^{CRE}+P14⁺ mice bearing CD8 T cells specific for the LCMV D^bGP₃₃₋₄₁ epitope (termed Cas9⁺P14, or C9P14). We expressed the backbone-optimized Cas9 single guide RNA (sgRNA, Grevet et al., 2018) together with a fluorescence-tracking marker in a retroviral (RV) vector (**Figure S1A**). To evaluate gene editing efficiency *in vivo*, we retrovirally transduced C9P14 cells *ex vivo* with either negative control sgRNA (sgCtrl, **Supplementary Table 1**) or sgRNA targeting *Pdcd1* (Encoding PD-1, sgPdcd1, **Supplementary Table 1**) following an optimized murine T cell RV transduction protocol (Kurachi et al., 2017) (**Figure S1B**). The double-positive populations of sgRNA (mCherry⁺) and Cas9 (GFP⁺) CD8 T cells (**Figure S1C**) were adoptively transferred into congenic recipient mice infected with the chronic strain of LCMV (clone13; LCMV-CI13) (**Figure S1B**). 9 days post infection (p.i.), sgRNA⁺C9P14 cells were isolated for phenotypic and gene editing evaluation. As expected, sgPdcd1 induced antigen specific CD8 T cells expansion 5 fold greater than the control sgRNA (**Figure S1D**), consistent with the genetic knockout of *Pdcd1* (Odorizzi et al., 2015). We found that the sgPdcd1 resulted in both a robust decrease of PD-1 protein level using flow cytometry (**Figure S1E**) and indel mutations in the corresponded genomic locus of *Pdcd1* using sanger-sequencing (**Figure S1F**). Furthermore, we confirmed the high gene editing efficiency of our system by designing sgRNAs targeting *Klrg1* and *Cxcr3* loci (**Figure S1G, Supplementary Table 1**). Collectively, this *in vitro* sgRNA RV transduction in C9P14 followed by *in vivo* adoptive transfer system provides a robust platform to investigate genetic regulatory network of murine CD8 T cells *in vivo*.

OptICS enables pooled genetic screening in CD8 T cells *in vivo*.

To enable *in vivo* pooled genetic screening in LCMV infection system, we decided to further optimize the

parameters of the C9P14 and retroviral sgRNA platform (**Figure 1A**). First, we determined a physiologically relevant number of adoptively transferred CD8 T cells for pooled genetic screening, as the T cell numbers can influence the outcome of infection or tumor models. For example, in the case of LCMV-Cl13 infection model, high numbers of adoptively transferred P14 CD8 T cells can cause lethal immunopathology or convert a chronic infection to an acutely resolved infection (Blattman et al., 2009) preventing the study of T_{EX} cells. We, therefore, limited the maximal number of adoptive transferred CD8 T cells to 1×10^5 per mouse (approximately 1×10^4 after take) that was previously shown not to trigger immunopathology or clearance of chronic infection (Chen et al., 2019b; Kao et al., 2011). Next, to evaluate the performance of our system, we performed pooled genetic screening against a focused set of 29 TFs in CD8 T cells *in vivo* using LCMV models. Previously, we found that sgRNA targeting functional important protein domains can substantially improve genetic screening efficiency, as both inframe and frameshift mutations contribute to generating loss-of-function alleles (Shi et al., 2015). We designed and cloned a sgRNA library targeting the DNA-binding domains of 29 TFs and other control genes (e.g. non-selected control sgRNAs and *Pdcd1*) with 4-5 sgRNAs per target. We found that increasing the average input coverage of more than 400 cells per sgRNA after CD8 T cells engraftment could increase the signal to noise ratio, and successfully identify hits, in comparison to 100 cells per sgRNA (**Figure S2A-S2B**). Third, we assessed the performance of our *in vivo* screen using P14 cells expressing heterogeneous versus homogeneous alleles of the LSL-Cas9 transgene. We observed that Cas9 heterozygous P14 cells outperformed Cas9 homozygous ones in terms of signal-to-noise ratio in different tissues and consistency between independent screens (**Figure S2A-S2C**). We speculated that this is presumably due to reduced off-target DNA damage in the heterozygous setting as we have recently noted for CRE recombinase (Kurachi et al., 2019). From these preliminary optimization screens, we identified *Batf*, *Irf4*, and *Myc* as essential for early T cell activation because genetic targeting of these genes potently inhibited T cell activation *in vivo* (**Figure S2A-S2B**), consistent with known roles for *Batf* and *Irf4* (Grusdat et al., 2014; Kurachi et al., 2014; Man et al., 2013; 2017; Quigley et al., 2010), and *Myc* (Lindsten et al., 1988; Wang et al., 2011) in T_{EFF} biology. Of note, this system was highly efficient with up to ~100-fold enrichment for genes essential for CD8 T cell responses (**Figure S2A-S2B**) and nearly 20-fold enrichment for genes that repress T cell activation and differentiation (**Figure S2D**). Thus, this platform, termed the Optimized T cell In vivo CRISPR Screening system (OpTICS), provides a robust method for focused *in vivo* CRISPR screening in CD8 T cells.

OpTICS identifies novel TF involved in T_{EFF} and T_{EX} cell differentiation.

To identify new TFs governing T_{EFF} and T_{EX} cell differentiation, we constructed another domain-focused sgRNA library against 120 TFs (**Supplementary Table 2**, candidate selection in Star Methods). This library has 675 sgRNAs total, including 4-5 sgRNAs per DNA-binding domain, positive selection controls (sg*Pdcd1*), and

non-selection controls (e.g. sgAno9, sgRosa26, etc.) (**Figure 1A**). With this 120-TF targeting sgRNA library, we next interrogated *in vivo* selection and sgRNA enrichment at 1 or 2 weeks p.i. with acutely resolving LCMV Arm (LCMV-Arm) or chronic LCMV-CI13 (**Figure 1A**). We examined C9P14 cells from 4 different anatomical locations (PBMC, spleen, liver and lung) to identify TFs that were broadly important for CD8 T cell responses to infection. In general, groups clustered by time point and infection, rather than anatomical location (**Figure S2E**). At 2 weeks p.i. the data for LCMV-Arm and LCMV-CI13 diverged (**Figure S2E**), consistent with different trajectories of T cell differentiation during acutely resolved versus chronic infections (Wherry et al., 2007). Focusing on the spleen, *Batf*, *Irf4* and *Myc* emerged as some of the strongest negative selected hits at both time points in both infections, consistent with the importance of these TFs for initial CD8 T cell activation and T_{EFF} differentiation (**Figure 1B-1C**). We also confirmed several other known effector-driving TFs including *Tbx21* (encoding T-bet), *Id2*, *Stat5a*, *Stat5b*, and components of the NF- κ B complex (**Figure 1B-1C**). In addition, several TFs with potential novel roles in T cell activation and differentiation were revealed including *Smad4*, *Smad7* and *Mybl2* (**Figure 1B-1C**).

Many screens are designed to identify loss of function targets such as the TF noted above. In addition to identifying genes necessary for initial CD8 T cell activation and differentiation, we also used the OpTICS system as an “UP” screen (Kaelin, 2017) to identify genes that *repressed* optimal T cell activation and T_{EFF} cell differentiation. Such genes, like *Pdcd1*, represent potential immunotherapy targets for improving efficacy of T cell responses in cancer or infections. PD-1 served as a prototypical positive control where, as expected, *Pdcd1*-sgRNAs were strongly positively selected across infections, time points and in all tissues (**Figure 1B-1D**). This screen also identified TFs that scored as antagonizing robust CD8 T cell responses (**Figure 1B-1C**). Among these, *Tcf7* (encoding TCF-1), *Tox* and *Smad2* have been implicated in limiting robust T_{EFF} cell differentiation, activation and/or expansion. In particular, TCF-1 promotes stem cell-like memory T cells in acutely resolved infections (Zhou et al., 2010) or T_{EX} precursors and progenitors during chronic infections (Chen et al., 2019b; Im et al., 2016; Utzschneider et al., 2016; Wu et al., 2016; Zhou et al., 2010); suppressing TCF-1 has also been shown to augment T_{EFF} cell differentiation (Chen et al., 2019b; Lin et al., 2016). *Tox* is an essential driver of T_{EX} cell fate and represses terminal T_{EFF} differentiation (Alfei et al., 2019; Khan et al., 2019; Seo et al., 2019; Yao et al., 2019). *Smad2* has been shown to limit T_{EFF} cell responses during both acute and chronic infection (Tinoco et al., 2009). We also identified *Nfatc2* and *Nr4a2* (**Figure 1C**), both of which have been implicated in fostering T cell exhaustion and thus limiting T_{EFF} responses (Chen et al., 2019a; Martinez et al., 2015). In addition, *Gata3* identified here has been implicated in driving T cell dysfunction and inhibiting T_{EFF} cell response (Singer et al., 2016). Thus, this screen identified key TFs known to restrain T_{EFF} differentiation and, in some cases, promote exhaustion.

This OpTICS screen also identified novel TFs that restrained optimal T_{EFF} differentiation. This set of genes

included *Atf6*, *Irf2*, *Erg* and *Fli1*, with *Fli1* among the strongest hits in repressing T_{EFF} cell differentiation. The identification of *Fli1* as a repressor of T_{EFF} differentiation occurred similarly in LCMV-Arm and LCMV-CI13 infections indicating a common role for this TF in restraining T_{EFF} biology in settings of acutely resolving or chronic infection. In both infections, *Fli1*-sgRNAs were the top ranking positively selected sgRNAs across different conditions (**Figure 1B-1D**). We therefore focused additional efforts on interrogating the biology of *Fli1* in CD8 T cell differentiation.

Fli1 is an ETS family TF with roles in hematopoiesis and other developmental pathways in non-immune cell types (Kruse et al., 2009; Pimanda et al., 2007; Tijssen et al., 2011). In hematopoiesis, *Fli1* has been implicated in regulating stem cell maintenance and differentiation (Cai et al., 2015). The role of *Fli1* in T_{EFF}, T_{MEM} or T_{EX} cells, however, is unknown. To interrogate this question, we selected 2 *Fli1*-sgRNAs (sgFli1_290 and sgFli1_360) and confirmed that these sgRNAs effectively edited the *Fli1* gene (70%-80% editing; **Figure S3A**) leading to reduced protein expression (**Figure 1E**). Targeting *Fli1* using these individual *Fli1*-sgRNAs in C9P14 cells *in vivo* resulted in 5-20 fold greater expansion at 1 and 2 weeks p.i. with either LCMV-Arm or LCMV-CI13 (**Figure 1F** and **S3B-S3E**). These data indicate repression of robust CD8 T cell expansion by *Fli1* in acutely resolving or developing chronic infection.

Genetic deletion of *Fli1* promotes robust T_{EFF}-differentiation during acutely resolved infection.

We next interrogated the differentiation state of *Fli1*-sgRNA (sgFli1) or Ctrl-sgRNA (sgCtrl) transduced C9P14 cells during acutely resolved infection. On Day 8 p.i., *Fli1* deletion reduced the proportion of the CD127^{Hi} memory precursors (T_{MP}), whereas the frequency KLRG1^{Hi} terminal effector (T_{EFF}) population remained unchanged at this time point consistent with a slight increase in the CD127^{Lo}KLRG1^{Lo} population (**Figure 2A**). These effects were more dramatic at Day 15 p.i. resulting in a reduction in the CD127^{Hi} T_{MP} population and, at this time point, an increase in the proportion of KLRG1^{Hi} T_{EFF} cells (**Figure 2A**). However, at both time points the absolute number of both T_{MP} and T_{EFF} was increased due to the proliferative expansion of *Fli1*-deficient CD8 T cells (**Figure 2A**). This skewing of T cell differentiation towards T_{EFF}-like populations was also observed when CX3CR1 and CXCR3 were used to identify T_{MEM}⁻ and T_{EFF}-like cells (Gerlach et al., 2016), with sgFli1 significantly enriching for the CX3CR1⁺CXCR3⁻ T_{EFF} population compared to the CX3CR1⁻CXCR3⁺ early T_{MEM} subset (**Figure 2B**). To further interrogate the causality of *Fli1* in these effects on CD8 T cell differentiation, we next enforced *Fli1* expression in WT LCMV-specific P14 cells using a retroviral (RV) based overexpression (OE) system (Kurachi et al., 2017). A ~5-fold reduction in responding *Fli1*-OE-RV transduced P14 cells was observed Day 8 and Day 16 p.i. compared to the empty vector control (**Figure 2C**). Furthermore, enforced *Fli1* expression also skewed responding P14 cells towards T_{MP} differentiation, with an increase in CD127^{Hi}KLRG1^{Lo} and CX3CR1⁻CXCR3⁺ populations at the expense of KLRG1^{Hi}CD127^{Lo} or CX3CR1⁺CXCR3⁻ T_{EFF} cells (**Figure**

2D-2E). Together, these data reveal a role for Fli1 in restraining T_{EFF} differentiation and promoting T_{MP} development during acute infection.

Fli1 antagonizes T_{EFF}-like differentiation during chronic infection.

During chronic viral infection, there is an early fate bifurcation for CD8 T cell responses where antiviral CD8 T cells develop into either T_{EFF}-like cells or form T_{EX} precursors that ultimately seed the mature T_{EX} population (Chen et al., 2019b; Khan et al., 2019). We therefore investigated the role of Fli1 in this cell fate decision during the first 1-2 weeks of chronic infection. As in acutely resolving infection, genetic perturbation of Fli1 resulted in a skewing of the virus-specific CD8 T cell response towards the T_{EFF} pathway, as defined by TCF-1⁺GrzmB⁺ or Ly108⁻CD39⁺ (**Figure 3A** and (Chen et al., 2019b)). Due to the 5-10-fold increase in total *Fli1*-deficient cells, the cell numbers of both the T_{EFF}-like and T_{EX} precursor populations were increased (**Figure S4A-S4B**). In contrast, enforced Fli1 expression not only resulted in lower cell numbers (**Figure S4C**), but also fostered formation of Ly108⁺CD39⁻ or TCF-1⁺GrzmB⁻ T_{EX} precursors (**Figure S4D-S4E**). Moreover, genetic perturbation of Fli1 resulted in an increased proportion of T_{EFF}-like cells marked by high CX3CR1 or Tim3 expression (**Figure 3B** and (Chen et al., 2019b; Zander et al., 2019)). These data were confirmed by enforced Fli1 expression during LCMV-Cl13 infection that again provoked the opposite effect (**Figure S4F**). Notably, PD-1 expression was unchanged and, unlike acutely resolved infection, KLRG1 expression was unaffected (**Figure 3B**).

To dissect the underlying mechanism by which Fli1 regulates CD8 T cell differentiation, we performed RNA-seq on sorted sgCtrl⁺ or sgFli1⁺ C9P14 cells on Day 9 of LCMV-Cl13 infection. Both sgRNAs targeting *Fli1* resulted in a similar transcription effect (**Figure 3C, S4G**). In contrast, the sgFli1⁺ C9P14 cells were transcriptionally distinct from the sgCtrl⁺ C9P14 cells with over 1400 genes differentially expressed between the two conditions (**Figure 3C, S4G**). Among the major changes were a robust increase in effector-associated genes such as *Prf1*, *Gzmb*, *Cd28*, *Ccl3* and *Prdm1* in the sgFli1⁺ C9P14 cells, whereas the sgCtrl⁺ C9P14s were enriched in T_{EX} precursor genes such as *Tcf7*, *Cxcr5*, *Slamf6* and *Id3* (**Figure 3C**). Gene Ontology enrichment analysis also identified cell division-associated and T cell activation-associated pathways in sgFli1⁺ C9P14 cells (**Figure 3D**), whereas sgCtrl⁺ C9P14s enriched in multiple metabolic pathways, in particular nucleotide, nucleoside and purine biosynthesis (**Figure 3E**). We next used gene set enrichment analysis (GSEA) to examine skewing between signatures of subpopulations during the early phase of chronic infection, when a divergence of differentiation into either T_{EFF}-like or T_{EX} precursor cell fates occurs. Indeed, the T_{EX} precursor signature (Chen et al., 2019b) was strongly enriched in sgCtrl⁺ C9P14 cells compared to the sgFli1⁺ C9P14 population whereas a T_{EFF} gene signature (Bensch et al., 2018) was strongly enriched in the sgFli1⁺ C9P14 population (**Figure 3F-3G**). Thus, Fli1 repressed optimal T_{EFF} differentiation in both acutely resolving and chronic infection and loss of Fli1 antagonized the development of T_{EX} cells. However, although genetic perturbation of *Fli1* drove an increase in expression of effector-associated genes at Day 9 of chronic infection, *Tox*, *Tox2* and *Cd28* were

also increased. This effect may suggest that although loss of Fli1 might enhance T_{EFF}-like biology and might not be at the expense of genes necessary to sustain responses in chronic infection of cancer.

Fli1 remodels the epigenetic landscape of CD8 T cells and antagonizes T_{EFF}-associated gene expression.

In acute myeloid leukemia, FLI1 co-localizes with the chromatin remodeler BRD4 (Roe et al., 2015). Moreover, the oncogenic EWS-FLI1 fusion protein can bind genomic microsatellites (Gangwal et al., 2008), trigger *de novo* enhancer formation via chromatin remodeling and inactivate existing enhancers by displacing ETS family members (Riggi et al., 2014). Though EWS-FLI1 and FLI1 have similar GGAA-binding motifs (Riggi et al., 2014; Roe et al., 2015), the prion-like domain from EWS changes the overall function of the EWS-FLI1 fusion likely leading to distinct mechanisms of action (Boulay et al., 2017). Thus, it is unclear how Fli1 affects epigenetic landscape changes in general, especially in developing T_{EFF}, T_{MEM} or T_{EX} cells.

To examine the role of Fli1 in supporting the epigenetic landscape of CD8 T cells, we performed ATAC-seq on sgFli1⁺ and sgCtrl⁺ C9P14 cells on Day 9 p.i. with LCMV-Cl13. Compared to sgCtrl⁺ C9P14 cells, the sgFli1⁺ group had considerable changes in chromatin accessibility (**Figure 4A**). Over 5000 open chromatin regions (OCRs) differed between the control and *Fli1*-perturbed groups with approximately equal numbers of peaks gained or lost (**Figure 4B-4D**). Most of these changes were located in intronic or intergenic regions consistent with *cis*-regulatory or enhancer elements (**Figure 4C**).

To define how these changes in OCRs could impact the differentiation of T_{EFF} or T_{EX} cells, we next assigned each OCR to the nearest gene to estimate genes that could be regulated by these *cis*-regulatory elements. T_{EFF}-associated genes, such as *Ccl3*, *Ccl5*, *Cd28*, *Cx3cr1* and *Prdm1*, gained chromatin accessibility in the sgFli1⁺ group (**Figure 4D**), consistent with the RNA-seq data. In contrast, there was decreased chromatin accessibility near genes involved in T cell progenitor biology such as *Tcf7*, *Slamf6*, *Id3* and *Cxcr5* (**Figure 4D**) in the sgFli1⁺ group. Moreover, the sgFli1⁺C9P14 cells had altered accessibility in the *Tox* (and *Tox2*) locus, but these changes included both increased and decreased accessibility across different peaks (**Figure 4D**), consistent with the complex transcriptional and epigenetic control of *Tox* expression (Khan et al., 2019). These changes in chromatin accessibility corresponded to changes in gene expression with ~1/3 of the genes that changed transcriptionally associated with a differentially accessible chromatin region (402 out of 1467) (**Figure 4E**). In general, increased accessibility correlated with increased transcription though there was a clear subset of regions where decreased accessibility corresponded to increased transcription suggesting potential negative regulatory elements controlled by Fli1 (**Figure 4F**).

To define the mechanisms by which these Fli1-mediated chromatin accessibility changes regulated T cell differentiation, we next defined the TF motifs present in the OCRs that were dependent on Fli1 for altered

accessibility. Among the OCRs that decreased in accessibility in the absence of Fli1, the most enriched TF motifs were for IRF1 and IRF2 (**Figure 4G**), potentially linking Fli1 activity to the role of IRF1 and IRF2 downstream of IFN signaling or to the regulation of cell cycle by these TFs (Choo et al., 2006). In the group of OCRs that increased in accessibility in the absence of Fli1, ETS and RUNX motifs were highly enriched (**Figure 4G**). In particular, the composite ETS:RUNX motif was by far the most changed with 18-fold enrichment (**Figure 4G**). These observations suggested that Fli1 may limit the activity of other ETS family members (e.g. ETS1, ETV1 or ELK1) or alter accessibility at ETS:RUNX binding sites (**Figure 4G**). Runx3 is a central driver of T_{EFF} differentiation and functions by directly regulating effector gene expression, coordinating and enabling the effector gene regulation via T-bet and Eomes and antagonizing TCF-1 expression (Cruz-Guilloty et al., 2009; Shan et al., 2017; Wang et al., 2018). Thus, a potential role for Fli1 in Runx3 biology would provide a mechanistic link between loss of Fli1 and improved T_{EFF} differentiation.

We next tested how Fli1 genomic binding was related to changes in chromatin accessibility and T_{EFF} biology, using Fli1 CUT&RUN (Skene et al. 2017). At Day 9 p.i. with LCMV-Cl13 >90% of the identified Fli1 binding sites were contained in OCRs detected by ATAC-Seq (**Figure S4H-S4I**). Specifically, Fli1 bound to OCRs of T_{EFF}-like genes such as *Cx3cr1*, *Cd28* and *Havcr2*. Chromatin accessibility increased at these locations upon Fli1 deletion (**Figure 4H**), resulting in increased transcription (**Figure 3C**) and protein expression (**Figure 3B and 4I**). In contrast, for genes involved in progenitor biology that were decreased in expression in the absence of Fli1 such as *Tcf7* and *Id3*, direct binding of Fli1 was not observed (**Figure S4H**), likely indicating that the major role of Fli1 is to safeguard against an overly robust T_{EFF} program rather directly enabling memory/progenitor biology. Furthermore, 78% of the sites where Fli1 was defined to bind by CUT&RUN increased in chromatin accessibility in the absence of Fli1; in contrast, 22% decreased in accessibility (**Figure 4J**), suggesting that Fli1 mainly functions to repress chromatin accessibility. Analyzing the DNA binding motifs in the Fli1 CUT&RUN data revealed the expected FLI1 motif. However, SP2, NFY1 and RUNX1 motifs were also significantly enriched where Fli1 bound (**Figure 4K**). Together with the increase in ETS:RUNX motifs in the *Fli1*-deficient ATAC-seq data above, these data support a model where Fli1 coordinates with RUNX family members to control T_{EFF} differentiation.

Enforced Runx3 expression synergizes with *Fli1*-deletion to enhance T_{EFF} responses

RUNX family TFs are key regulators of CD8 T cell biology. In particular, Runx3 is central to the transcriptional cascade that coordinates T_{EFF} differentiation (Cruz-Guilloty et al., 2009; Wang et al., 2018). Runx3 also antagonizes a follicular-like CD8 T cell fate by inhibiting TCF-1 expression (Shan et al., 2017) and fosters the development of tissue and tumor resident CD8 T cells (Milner et al., 2017). Runx1, in contrast, is antagonized by Runx3 during T_{EFF} differentiation (Cruz-Guilloty et al., 2009). The roles of Runx1 and Runx3 in T_{EX}

development in the early phase of chronic infection are less clear. Because T_{EFF} and T_{EX} are opposing fates in chronic infection (Chen et al., 2019b; Khan et al., 2019; Yao et al., 2019; Zander et al., 2019) and ETS:RUNX motifs become more accessible in the absence of Fli1, we hypothesized that a RUNX-Fli1 axis might influence T_{EFF} versus T_{EX} differentiation. We tested whether Runx1 or Runx3 expression in *Fli1*-deficient CD8 T cells would impact T_{EFF} differentiation in early chronic infection.

Enforced expression of Runx1 in WT P14 cells reduced cell numbers at Day 7 p.i. with LCMV-Cl13 infection (**Figure S5A**) suggesting that Runx1 antagonized CD8 T cell activation and differentiation. Moreover, Runx1-OE fostered formation of $\text{Ly108}^+\text{CD39}^- T_{\text{EX}}$ precursors at the expense of the more T_{EFF} -like $\text{Ly108}^-\text{CD39}^+$ population at this early time point (**Figure S5A**). Next, to interrogate the impact of enforced Runx1 expression in the absence of Fli1, we used a dual RV transduction approach and combined control or Fli1 sgRNA RV transduction with either empty or Runx1 expressing RVs. Singly versus dually transduced cells were distinguished using VEX (for sgRNA) and mCherry. C9P14 cells were transduced and adoptively transferred into LCMV-Cl13-infected mice and the double transduced (i.e. $\text{GFP}^+\text{VEX}^+\text{mCherry}^+$) C9P14 cells were analyzed at Day 8 p.i. (**Figure 5A**). Dual-transduction was efficient and allowed robust detection of $\text{GFP}^+\text{VEX}^+\text{mCherry}^+$ C9P14 cells (**Figure S5B**). In the $\text{sgFli1}+\text{Runx1-OE}$ group the number of $\text{GFP}^+\text{VEX}^+\text{mCherry}^+$ C9P14 cells was reduced and there were fewer $\text{Ly108}^-\text{CD39}^+$ cells. In contrast the $\text{sgFli1}+\text{Empty-RV}$ group had an increase in the $\text{GFP}^+\text{VEX}^+\text{mCherry}^+$ C9P14 cell population and these cells were skewed towards the $\text{Ly108}^-\text{CD39}^+ T_{\text{EFF}}$ -like fate (**Figure 5B-5D, S5C**) as above. However, in the *Fli1*-deficient setting where there is enhanced CD8 T cell expansion, Runx1 overexpression reduced the magnitude of the response and partially reversed the skewing towards the $\text{Ly108}^-\text{CD39}^+ T_{\text{EFF}}$ -like fate caused by loss of Fli1 (**Figure 5B-5D**).

We next investigated the impact of enforced expression of Runx3 in the absence of Fli1 using the same dual transduction approach (**Figure 5A, 5E-5G, S5D-S5E**). Enforced expression of Runx3 alone (in the sgCtrl^+ group), modestly increased the magnitude of the CD8 T cell response but robustly skewed the $\text{GFP}^+\text{VEX}^+\text{mCherry}^+$ C9P14 population towards a $\text{CD39}^+\text{Ly108}^- T_{\text{EFF}}$ -like population (**Figure 5E-5G**). These effects were more dramatic in the absence of Fli1 with greater numerical amplification and even further skewing towards $\text{CD39}^+\text{Ly108}^- T_{\text{EFF}}$ -like cells in the $\text{sgFli1}+\text{Runx3-OE}$ enforced expression group in both proportion and cell number (**Figure 5E-5G**). While the $\text{sgFli1}+\text{Runx3-OE}$ group shows reducing the frequency of the T_{EX} precursor population, this group did not show a cell number reduction of this population (**Figure 5E and 5G; S5E**). Taken together, these data support a model where loss of Fli1 reveals ETS:RUNX motifs that can be used by Runx1 and/or Runx3. However, whereas Runx3 drives a more T_{EFF} -like population, an effect amplified in the absence of *Fli1*, Runx1 appears to antagonize T_{EFF} generation, in agreement with the opposing functions of Runx1 and Runx3 (Cruz-Guilloty et al., 2009). Thus, Fli1 restrains the T_{EFF} promoting activity of Runx3 function by restricting genome access and protecting ETS:RUNX binding sites. These data reveal Fli1, Runx3

and perhaps Runx1 (as a modest Runx3 antagonist) as key regulators of the fate choice between T_{EFF} and T_{EX} early after initial activation.

Augmented T_{EFF} cell responses in the absence of Fli1 improve protective immunity against pathogens.

The data above provoke the question of whether loss of Fli1 would improve control of infections due to the augmented T_{EFF} differentiation. To test this idea, we used LCMV-CI13 to investigate protective immunity during chronic infection and two models of acute infection with influenza virus (PR8) or *Listeria monocytogenes* (LM) each expressing the LCMV GP₃₃₋₄₁ epitope (PR8_{GP33} and LM_{GP33}) recognized by P14 cells (**Figure 6A**).

During LCMV-CI13 infection, adoptive transfer of sgCtrl⁺ C9P14 cells conferred a moderate degree of viral control compared to the no transfer condition (NT, **Figure 6B**) as expected (Blattman et al., 2009). However, when we compared the two transferred groups, sgFli1⁺ C9P14 provided substantially improved control of viral replication at ~2 weeks p.i. (**Figure 6B**), demonstrating a phenotypic benefit due to loss of Fli1 even in chronic viral infection where induction of exhaustion is a major barrier to effective protective immunity.

We next evaluated the impact of loss of Fli1 during acutely resolving infections. During influenza-PR8_{GP33} infection, mice receiving sgFli1⁺ C9P14 cells lost less weight than control non-transferred mice or mice receiving sgCtrl⁺ C9P14 cells (**Figure 6C**). This decreased weight loss was associated with better control of viral replication in the lungs of mice receiving sgFli1⁺ but not sgCtrl⁺ C9P14 cells (**Figure 6D**). In this setting, there was variation in the magnitude of the sgFli1⁺ C9P14 expansion in the lungs following PR8_{GP33} infection (**Figure S6A-S6C**). This heterogeneity in the T cell responses was associated with differences in viral control, with some mice nearly eliminating viral RNA by this time point (**Figure 6D**) and recovering from infection-associated weight loss. Therefore, we tested whether there was a relationship between recovery from infection and/or control of viral replication and the magnitude of the C9P14 response. Indeed, the overall magnitude of the C9P14 response was lower in mice that had recovered, consistent with prolonged viral replication and higher antigen load driving increased T cell expansion in mice that had not yet controlled the infection (**Figure S6A-S6B**). Notably, 6 out of 12 of the mice receiving sgFli1⁺ C9P14 cells had controlled disease by this time point, as compared to only 1 out of 11 mice receiving sgCtrl⁺ C9P14 (**Figure 6D, S6B**). In the group of mice still harboring viral RNA in the lungs, sgFli1⁺ C9P14 cells had expanded to substantially higher numbers than sgCtrl⁺ C9P14 cells (**Figure S6B**). A similar difference in T_{EFF} cell expansion was also observed in spleen where sgFli1⁺ C9P14 cells were ~3 times more numerous than the sgCtrl⁺ group (**Figure S6C**).

Loss of Fli1 conferred a similar advantage following LM_{GP33} infection. Although both sgCtrl⁺ and sgFli1⁺ C9P14 cells improved survival following a high dose LM_{GP33} challenge (**Figure 6E**), sgFli1⁺ C9P14 cells resulted in substantially better control of bacterial replication in the spleen and liver compared to the sgCtrl⁺ C9P14 cells at D7 p.i. (**Figure 6F**). Consistent with the influenza virus setting, this improved protective immunity was

associated with greater numerical expansion of sgFli1⁺ C9P14 cells compared to the sgCtrl⁺ group (**Figure S6D**). Thus, deficiency in Fli1 confers a substantial benefit on T_{EFF} cell expansion and protective immunity during chronic LCMV-CI13 infection, respiratory influenza virus infection, and systemic infection with an intracellular bacterium.

Loss of Fli1 in CD8 T cells enhances immunity to tumors.

We next asked whether the Fli1 deficiency could also mediate increased protective immunity in a cancer setting. Thus, we next employed a subcutaneous B16_{GP33} tumor model. Tumor-bearing mice received equal numbers of sgCtrl⁺ or sgFli1⁺ C9P14 cells on day 5 post tumor inoculation (p.t.) (**Figure 7A**). We used Rag2^{-/-} recipient mice to isolate the effects of sgCtrl⁺ versus sgFli1⁺ C9P14 cells (**Figure 7A**). In this setting sgFli1⁺ C9P14 cells robustly controlled tumor progression compared to non-transferred mice or the sgCtrl⁺ C9P14 group (**Figure 7B**). Furthermore, tumor weight was significantly lower in the sgFli1⁺ C9P14 group compared to either control group at endpoint (**Figure 7C**). Although there was not a clear difference in the number of C9P14 cells/g of tumor, this tumor control was associated with a significant increase in Ly108⁺CD39⁺ donor C9P14 in the sgFli1⁺ group, consistent with a shift towards the more T_{EFF}-like population (**Figure 7D-7E**). In the spleen, however, there was a significant increase in sgFli1⁺ C9P14 cell numbers, as well as the proportion of Ly108⁺CD39⁺ cells compared to the sgCtrl⁺ group (**Figure 7F-7G**). We next extended these findings into immune competent mice using B16_{GP33} tumors. We used Cas9⁺ C57BL/6 recipient mice to prevent rejection of the C9P14 donor cells to allow responses to be analyzed for an extended period of time (**Figure S7A**). In this setting, sgFli1⁺ C9P14 cells again conferred substantial benefit on tumor control (**Figure S7B-S7C**) compared to sgCtrl⁺ C9P14 cells. Furthermore, this improved tumor control was associated with an increase in the Ly108⁺CD39⁺ T_{EFF}-like population in the tumor, draining lymph node (dLN) and spleen, as well as the increased C9P14 cell numbers in the dLN and spleen (**Figure S7D-S7G**). Thus, genetic deletion of Fli1 conferred a substantial benefit on tumor control indicating a central role for Fli1 in coordinating and restraining protective T_{EFF} responses during tumor invasion and progression. Together, these data show that loss of Fli1 results in improved protective immunity, in the setting of systemic and local, acutely resolving and chronic infections, as well as tumor progression. In these settings enhanced CD8 T cell expansion and a shift in differentiation highlight the role of Fli1 as a key regulator of CD8 T cell differentiation. These data suggest that manipulating Fli1-related pathways could be a viable strategy for therapeutics for infectious disease and cancer.

Discussion

Considerable current efforts focus on improving immunotherapy for cancer and chronic infections through a better understanding of the biology of T_{EX} and T_{EFF} differentiation. In this study, we used a focused *in vivo* CRISPR screening approach to specifically interrogate the mechanisms governing T_{EX} versus T_{EFF} differentiation. Among our screening hits, we identified *Fli1* as a key TF that safeguards the transcriptional and epigenetic commitment to full T_{EFF} differentiation. *Fli1* also negatively regulated CD8 T cell expansion and genetic loss of *Fli1* resulted in considerable improvement in antigen-specific CD8 T cell expansion generating more T_{EFF} without numerical loss of progenitor or memory precursor populations. Mechanistically, *Fli1* limited epigenetic accessibility to ETS:RUNX sites, preventing *Runx3* from fully enabling an effector program. As a result, deleting *Fli1* robustly improved protective immunity in multiple models of acute infection, chronic infection and cancer, thus identifying *Fli1* as a novel regulator of the T_{EFF} versus T_{EX} differentiation programs and a target for future immunotherapy strategies.

Recent advances in CRISPR-based screening approaches have allowed the dissection of *in vitro* T cell activation (Shang et al., 2018; Shifrut et al., 2018) and *in vivo* responses to infections and tumors (Dong et al., 2019; LaFleur et al., 2019b; Wei et al., 2019; Ye et al., 2019). To better understand the fate commitment of T_{EFF} and T_{EX} , we developed OpTICS, an *in vivo* screening system that does not disrupt T cell maturation or the very early signals of T cell activation. This screen revealed known targets essential for positive regulation of the primary steps in T cell activation and differentiation including *Batf*, *Irf4* (Kurachi et al., 2014; Man et al., 2013) and *Myc* (Lindsten et al., 1988; Wang et al., 2011) as well as TFs that have key roles in developing and controlling the effector program such as members of the NF- κ B family and the T-box TF, T-bet. A key goal of this screen was to identify TFs that restrain full T_{EFF} differentiation and prevent optimal protective CD8 T cell responses during chronic infection and cancer. Genes known to promote T cell exhaustion, like *Tox*, *Nr4a1* and *Nr4a2* (Alfei et al., 2019; Chen et al., 2019a; Khan et al., 2019; Liu et al., 2019; Scott et al., 2019; Seo et al., 2019; Yao et al., 2019) were revealed, as was *Tcf7* due to its the ability to antagonize T cell activation and T_{EFF} differentiation (Chen et al., 2019b). We also, however, identified several novel negative regulators of T_{EFF} differentiation, including *Smad2*, *Erg* and *Fli1*. Indeed, genetic loss of *Fli1* improved protective immunity in multiple settings of acute or chronic infection and cancer. This enhanced protection by *Fli1*-deficient CD8 T cells was robust and consistent across models. Moreover, unlike the effect seen with of the loss T_{EX} -driving TF *Tox*, in which responses cannot be sustained during chronic infection or cancer due to loss of T_{EX} progenitor cells (Khan et al., 2019, Seo et al., 2019), deficiency in *Fli1* did not diminish the T_{EX} progenitor population. These observations may be of particular relevance for immunotherapy, where effective immune control is often limited by T cell exhaustion. It remains unknown whether this beneficial effect on tumor immunity is due to increased T cell numbers, de-repressed T_{EFF} differentiation or a combination of these effects. It is also possible that

enhanced Runx3 activity fosters more efficient tissue residency, an effect that would be consistent with improved immunity in the influenza virus model. Finally, given the ability to apply CRISPR-mediated genetic manipulations in cellular therapy settings (Stadtmauer et al., 2020; Xu et al., 2019), it is possible to envision improved CAR T cell therapies through targeting Fli1 or related pathways.

Fli1 has a role in hematopoietic stem cell differentiation and co-localizes with other TFs such as Gata1/2 and Runx1 (Tijssen et al., 2011). Here, we find that genetic perturbation of Fli1 significantly increased chromatin accessibility at ETS:RUNX motifs in antigen-specific CD8 T cells responding to viral infection. Moreover, the effect of enforced Runx3 expression is enhanced in the absence of Fli1. These observations suggest that Fli1 prevents accessibility to RUNX binding sites, restricting the activity of the effector-promoting TF Runx3. Moreover, Runx3 can coordinate epigenetic changes at loci encoding other effector-promoting TFs (Wang et al., 2018). Runx1 likely antagonizes Runx3 and vice versa, though Runx3 appears to dominate in settings of T cell activation (Cheng et al., 2008; Cruz-Guilloty et al., 2009). Our data also suggest that Fli1 can cooperate with Runx1 to restrain T_{EFF} differentiation. Together, these data suggest a model where Fli1, in combination with Runx1, prevents efficient genome accessibility or activity of Runx3 and thus restrains a full effector gene program and a positive feed-forward effector promoting activity of Runx3. Thus, genetic deletion of Fli1 de-represses T_{EFF} differentiation, at least partially by creating opportunities for more efficient Runx3 activity.

Recent work has begun to define the transcriptional circuitry that directs fate decisions between terminal T_{EFF} , T_{MEM} and T_{EX} . Many of these mechanisms that promote one cell fate directly repress the opposing fate. For example, Tox promotes T_{EX} while repressing T_{EFF} , TCF-1 promotes T_{MEM} or T_{EX} at the expense of T_{EFF} and Blimp-1, T-bet, Id-2, and others drive T_{EFF} and repress T_{MEM} (Kaeck and Cui, 2012). The identification of Fli1 as a type of genomic “safeguard” against over-commitment to effector differentiation reveals several novel concepts. First, previous TF circuits that prevent T_{EFF} differentiation to preserve T_{MEM} or T_{EX} differentiation such as TCF-1 or Tox have been essentially binary (Alfei et al., 2019; Chen et al., 2019b; Im et al., 2016; Khan et al., 2019; Utschneider et al., 2016). Fli1 appears to represent a distinct type of damper on an otherwise robust feed-forward effector transcriptional circuit. By restraining Runx3 node in the effector wiring, Fli1 tempers a central step that not only directly controls expression of key effector genes but also positively reinforces other cooperating effector TFs. However, unlike TCF-1 and Tox, Fli1 does not appear to be required for progenitor biology and the number of both T_{EFF} cells and T_{MP} (in acutely resolved infections) or T_{EX} progenitor cells (in chronic infection) were increased in the absence of Fli1. Thus, by interrupting this “damper” in the circuit, rather than deleting the master switch of T_{MP} or T_{EX} differentiation it may be possible to augment beneficial aspects of short-term protective immunity without compromising long-term immunity. Second, our data reveal a mechanism of competition for epigenetic access between Fli1 and ETS:RUNX family members. These effects

may manifest because Fli1 occupies genomic locations that can be bound by ETS:RUNX family TFs that would catalyze chromatin accessibility changes; alternatively, these effects may be due to chromatin changes coordinated by Fli1 itself. It is interesting to note that the EWS-FLI1 fusion recruits the BAF complex to initiate chromatin changes in key regions in cancer cells (Boulay et al., 2017), consistent with the major changes in chromatin accessibility observed in the absence of Fli1 in CD8 T cells here. Thus, the role of Fli1 in CD8 T cells likely involves a chromatin accessibility-based mechanism to restrain ETS:RUNX driven effector biology, though other effects through IRF1/IRF2 may also exist.

The current studies demonstrate a major beneficial effect of loss of Fli1 on protective immunity in multiple settings of acutely resolved or chronic infection and cancer. Although clinical benefit has been observed in some settings due to partial loss of Tox (Khan et al., 2019) or genetic loss of Tox2 with knockdown of Tox (Seo et al., 2019), there may not be substantial benefit for overall protective immunity because complete loss of Tox diverts CD8 T cells entirely towards terminal T_{EFF} differentiation. In contrast, in the absence of Fli1 there was robust and consistent improvement in protective immunity across models. Of particular relevance for immunotherapy, deleting Fli1 improved control of both tumor growth and chronic LCMV infection where the induction of exhaustion typically limits immunity and in the tumor setting. For the former, established B16_{gp33} tumors were effectively controlled for 3 weeks, consistent with the notion that loss of Fli1 provides durable protection in the setting of cancer. It will be interesting to determine in future studies whether this beneficial effect on tumor immunity is due to increased T cell numbers, the de-repression of T_{EFF} differentiation by loss of Fli1, enhanced transcription of specific effector gene programs or a combination of these effects. It is also possible that enhanced Runx3 activity fosters more efficient tissue residency effects, a change that would be consistent with improved immunity in the influenza virus model. Finally, given the ability to apply CRISPR-mediated genetic manipulations in cellular therapy settings (Stadtmauer et al., 2020; Xu et al., 2019) it might be possible to envision clinical benefits with CAR T cells by targeting Fli1 or related pathways.

Thus, the OpTICS platform provides a highly robust *in vivo* platform to screen genes involved in regulating of CD8 T cell differentiation as it relates to tumor immunotherapy. This highly focused and optimized platform allows for a 20-100-fold enrichment of sgRNA detection and considerable resolution for gain-of-function screening. In addition to the novel role of Fli1 revealed here, many other potential targets for exploration exist from this screen. Moreover, using OpTICS to extend from this TF focused biology to other areas of cellular biology should provide a robust platform for future discovery.

Acknowledgement

We thank all members of the Wherry Lab and Shi Lab for helpful discussions. This work was supported by grants from the NIH (AI105343, AI117950, AI082630, AI112521, AI115712, AI108545, CA210944) and Stand Up 2 Cancer to E.J.W.; NIH grant CA234842 to Z.Chen; NIH grant CA009140 to J.R.G.; NIH grant MH109905, HG010480 and Searle Scholar's Program to A.B.. E.J.W. is supported by the Parker Institute for Cancer Immunotherapy which supports the cancer immunology program at UPenn; S.F.N. is supported by an Australia NH&MRC C.J. Martin Fellowship (1111469) and the Mark Foundation Momentum Fellowship; J.R.G. is supported by Cancer Research Institute-Mark Foundation Fellowship.

Author Contribution

Z.Chen, J.S. and E.J.W. designed the complete study; Z.Chen performed the mouse experiments, flow cytometry and sorting experiments with the help of Z.Cai, A.E.B., S.F.N. and E.F.; E.A. and Z.Chen performed sgRNA library construction with the support of J.S., J.R.G., O.K. and S.M.; E.A., E.F., Z.Cao, Z. Wen performed RV-sgRNA vector constructions; Z.Chen performed RV construction, production and transduction with the support from J.E.W., M.K. and N.A.S.; Z.Chen, O.K. and A.E.B. optimized *in vivo* screening conditions; Z.Chen and Y.H. performed sgRNA enrichment analysis with help from J.S. and A.B.; Z.Chen, Y.H. and S.M. performed RNA-seq and analysis; O.K., Z.Chen and S.M. performed ATAC-seq and analysis; Z.Z., H.H and Z.Chen performed CUT&RUN and analysis with the support of S.L.B.; Z.Chen performed LM infection; M-A. A. and Z.Chen performed influenza infection and detection assays; Z.Chen, K.N. and V.E. performed plaque assays of LCMV-Cl13; Z.Chen and S.F.N. performed B16 tumor experiments; A.G., A.E.B. and J.E.W. made key editorial contributions to the manuscript; Z.Chen, J.S. and E.J.W. wrote the manuscript.

Declaration of Interests

E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar, and Surface Oncology. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. has a patent licensing agreement on the PD-1 pathway with Roche/Genentech.

Figure Legends

Figure 1. Dissecting transcriptional programs during CD8 T cell response using OpTICS system.

- A. Experimental design for Optimized T cell In vivo CRISPR Screening (OpTICS). On Day 0(D0), CD8 T cells were isolated from CD45.2⁺ C9P14 donor mice and activated *in vitro*; CD45.1⁺ WT recipient mice were infected with LCMV. On D1 p.i., activated C9P14 cells were transduced with the retroviral (RV) sgRNA library for 6 hours. On D2 p.i., Cas9⁺sgRNA⁺ P14 cells were sort purified; 5-10% of the sorted cells were directly frozen for D2 baseline (T0 time point), and the rest were adoptively transferred into LCMV-infected recipient mice. Cas9⁺sgRNA⁺ P14 cells were then isolated from different organs of recipient mice on the indicated days by MACS and FACS sorting (T1 time point). Genomes were isolated from the Cas9⁺sgRNA⁺ P14 cells isolated at the indicated time points and conditions. Targeted PCR with sequencing adaptors for the sgRNA cassettes was performed and PCR products were sequenced. The CRISPR Score (CS) was calculated according to the formula shown.
- B. The CS comparing T1 time point to T0 time point (D2 baseline) for different target genes from Cas9⁺sgRNA⁺ cells from spleen on D8 p.i. of Arm, D15 p.i. of Arm, D9 p.i. of CI13 and D14 p.i. of CI13. X-axis shows targeted genes; y-axis shows the CS of each targeted gene (calculated using 4-5 sgRNAs).
- C. Heatmap of CS for targeted genes. Heatmap ranks the geometric means of CS for each targeted gene. Normalization details in Star Methods.
- D. Distribution of Ctrl, *Pdcd1* and *Fli1* sgRNAs. Axis represents log₂ fold change (FC). Histogram shows distribution of all sgRNAs. Red bars represent targeted sgRNAs, grey bars represent all other sgRNAs.
- E. Western blot for Fli1 protein from sorted Cas9⁺sgFli1⁺ P14 cells and paired Cas9⁺sgFli1⁻ P14 cells from spleen. Two *Fli1*-sgRNAs (sgFli1_290 and sgFli1_360) were used. Pooled mice were used in these experiments (3-5 mice for Arm, 10-15 mice for CI13). Bar graph represents the normalized band intensity of Fli1. The normalized band intensity of Fli1 was first normalized to GAPDH, then a ratio between Cas9⁺sgFli1⁺ versus Cas9⁺sgFli1⁻ was calculated and presented in the bar graph.
- F. Normalized Cas9⁺sgRNA (VEX)⁺ cell numbers from spleen for Ctrl-sgRNA(sgCtrl) and 2 *Fli1*-sgRNA (sgFli1_290 and sgFli1_360) groups on D8 p.i. of Arm, D15 p.i. of Arm, D9 p.i. of CI13 and D14 p.i. of CI13. Cell numbers normalized to the sgCtrl group based on D2 *in vitro* transduction efficiency (see Figure S3B and S3D).

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.001$ versus control (One-Way Anova analysis). Data are representative of 4 independent experiments (mean \pm s.e.m.) with at least 4 mice/group for F.

Figure 2. Fli1 inhibits T_{EFF} cell proliferation and differentiation during acute infection.

- A. Flow cytometry plots and statistical analysis of KLRG1^{Hi}CD127^{Lo} Terminal Effectors (TEs) and KLRG1^{Lo}CD127^{Hi} Memory Precursors (MPs). Frequencies (left) and numbers (right) from spleen for sgCtrl and 2 sgFli1 groups on D8 and D15 p.i. of Arm. Gated on Cas9(GFP)⁺ sgRNA(VEX)⁺ P14 cells.
- B. Flow cytometry plots and statistical analysis of CX3CR1⁺CXCR3⁻ T_{EFF} cells and CX3CR1⁻CXCR3⁺ early T_{MEM} cells frequencies (left) and numbers (right) from spleen for sgCtrl and 2 sgFli1 groups on D8 and D15 p.i. of Arm. Gated on Cas9⁺sgRNA⁺ P14 cells.
- (C-E) Experimental design. On D0, CD45.1⁺ P14 cells were activated and recipient mice were infected with Arm; On D1 p.i., activated P14 cells were transduced with Empty-RV or Fli1-over expression(OE)-RV for 6 hours. On D2 p.i., VEX⁺ P14 cells were purified by sorting from Empty-RV or Fli1-OE-RV groups, and 5 x 10⁴ cells were adoptively transferred into the infected recipient mice.
- C. Flow cytometry plots of CD45.2⁺VEX⁺ cell frequency and statistical analysis of CD45.2⁺VEX⁺ cell number for Empty-RV and Fli1-OE-RV conditions.
- D. Flow cytometry plots and statistical analysis of KLRG1^{Hi}CD127^{Lo} TE and KLRG1^{Lo}CD127^{Hi} MP frequencies from spleen for Empty-RV and Fli1-OE-RV groups on D8 and D15 p.i. of Arm. Gated on VEX⁺ P14 cells.
- E. Flow cytometry plots and statistical analysis of CX3CR1⁺CXCR3⁻ T_{EFF} cell and CX3CR1⁻CXCR3⁺ early T_{MEM} cell frequencies from spleen for Empty-RV and Fli1-OE-RV groups on D8 and D15 p.i. of Arm. Gated on VEX⁺ P14 cells.

P*<0.05, *P*<0.01, ****P*<0.001, *****P*<0.001 versus control (two-tailed Student's *t*-test and One-Way Anova analysis). Data are representative of 2-4 independent experiments (mean±s.e.m.) with at least 3 mice/group.

Figure 3. Fli1 antagonizes T_{EFF}-like cell differentiation during chronic infection.

- A. Flow cytometry plots and statistical analysis of Ly108⁻CD39⁺ or TCF-1⁻Gzmb⁺ T_{EFF}-like cells and Ly108⁺CD39⁻ or TCF-1⁺Gzmb⁻ T_{EX} precursor frequencies from spleen for sgCtrl and 2 sgFli1 groups on D8 and D15 p.i. of Cl13. Gated on the Cas9(GFP)⁺sgRNA(VEX)⁺ P14 cells.
- B. Statistical analysis of CX3CR1⁺ and Tim-3⁺ frequencies, and KLRG1 and PD-1 MFIs from spleen for sgCtrl and 2 sgFli1 groups on D8 and D15 p.i. of Cl13. Gated on the Cas9⁺sgRNA⁺ P14 cells.
- C. Heatmap showing differentially expressed genes between sgCtrl and 2 sgFli1 groups.

- D. Gene Ontology (GO) enrichment analysis for the sgFli1 groups.
 - E. GO enrichment analysis for the sgCtrl groups.
 - F. Gene Set Enrichment Analysis (GSEA) of T_{EX} precursor signature (adapted from Chen et al. 2019) between sgCtrl and sgFli1 groups.
 - G. GSEA of T_{EFF}-like signature (adapted from Bengsch et al. 2018) between sgCtrl and sgFli1 groups.
- * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.001$ versus control (two-tailed Student's *t*-test and One-Way Anova analysis). Data are representative of 4 independent experiments (mean±s.e.m.) with at least 4 mice/group for A and B.

Figure 4. Fli1 reshapes the epigenetic profile of CD8 T cells and inhibits T_{EFF}-associated gene expression.

- A. PCA plot of ATAC-seq data for sgCtrl, sgFli1_290 and sgFli1_360 groups on D9 p.i. of Cl13.
- B. Overall open chromatin region (OCR) peak changes for sgFli1 groups compared to sgCtrl group.
- C. Categories of *Cis*-element OCR peaks that changed between sgCtrl and sgFli1 groups. Left plot represents all changes; right plot represents changes for increased or decreased accessibility.
- D. Heatmap shows differentially accessible peaks between sgCtrl group and 2 sgFli1 groups (adjusted p -value <0.05 , Log₁₀ Fold Change >0.6). Some of the nearest genes assigned to the peaks are listed.
- E. Overlapping Venn plot of the genes with differentially accessible (DA) peaks and differentially expressed genes from Figure 3C.
- F. Pearson correlation of the peak accessibility of the nearest genes versus the differential expression of the genes.
- G. Transcription factor (TF) motif gain or loss associated with loss of Fli1. X-axis represents the log P -value of the motif enrichment. Y-axis represents the fold change of the motif enrichment. Targeted motifs in the changed OCR between the sgCtrl and sgFli1 groups were compared to the whole genome background to calculate p -value and fold change.
- H. IgG or Fli1 binding signals from CUT&RUN on P14 cells on D8 p.i. of Cl13 and OCR signals detected by ATAC-seq for sgCtrl-sgRNA, sgFli1_290 and sgFli1_360 groups at the *Cd28*, *Cx3cr1*, and *Havcr2* loci.
- I. Histogram of CD28 staining and statistical analysis for sgCtrl, sgFli1_290 and sgFli1_360 groups on D8 Cl13 p.i. Grey shows CD28 staining of CD44⁻ naïve T cell.
- J. Heatmap shown differentially accessible (DA) peaks overlapped with the Fli1 CUT&RUN binding peaks between sgCtrl group and 2 sgFli1 groups. Some of the nearest genes assigned to the peaks are listed.

K. Top 4 enriched TF motifs in the Fli1 CUT&RUN peaks are listed.

* $P < 0.05$, ** $P < 0.01$ versus control (One-Way Anova analysis). Data are representative of 2 independent experiments (mean \pm s.e.m.) with at least 5 mice/group for I.

Figure 5 Overexpression of Runx1 inhibits the phenotypes of *Fli1*-deficiency while overexpression of Runx3 enhances *Fli1*-deficient effects.

A. Experimental design. On D0, CD8 T cells were isolated from CD45.2⁺ C9P14 donor mice and activated; CD45.1⁺ WT recipient mice were infected with LCMV CI13. On D1 p.i., activated C9P14 cells were transduced with sgRNA-RV or OE-RV for 12 hours, and 1×10^5 transduced cells were adoptively transferred into infected recipient mice.

B-D. Flow cytometry plots (B) and statistical analysis (C-D) of VEX⁺mCherry⁺ C9P14 cells and Ly108⁻CD39⁺/Ly108⁺CD39⁻ C9P14 cells from spleen for sgCtrl-VEX + Empty-mCherry, sgCtrl-VEX + Runx1-mCherry, sgFli1_290-VEX + Empty-mCherry and sgFli1_290-VEX + Runx1-mCherry on D8 p.i. of CI13. Gated on Cas9(GFP)⁺CD45.2⁺ P14 cells.

E-G. Flow cytometry plots (E) and statistical analysis (F-G) of VEX⁺mCherry⁺ C9P14 cells and Ly108⁻CD39⁺/Ly108⁺CD39⁻ C9P14 cells from spleen for sgCtrl-mCherry + Empty-VEX, sgCtrl-mCherry + Runx3-VEX, sgFli1_290-mCherry + Empty-VEX and sgFli1_290-mCherry + Runx3-VEX at D8 p.i. of CI13. Gated on Cas9⁺CD45.2⁺ P14 cells.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.001$ versus control (One-Way Anova analysis). Data are representative of 2 independent experiments (mean \pm s.e.m.) with at least 5 mice/group.

Figure 6. *Fli1*-deficiency in CD8 T cells leads to better protective immunity against infections.

A. Experimental design. On D0, CD8 T cells were isolated from CD45.2⁺ C9P14 donor mice and activated; CD45.1⁺ WT recipient mice were infected with LCMV CI13, Influenza virus PR8-GP33 or *Listeria Monocytogenes*-GP33 (LM-GP33). On D1 p.i., activated C9P14 cells were transduced with sgCtrl or sgFli1 RV for 6 hours. On D2 p.i., Cas9⁺sgRNA(VEX)⁺ P14 cells were purified by flow cytometry for sgCtrl or sgFli1 groups, and adoptively transferred into the infected recipient mice. For LCMV-CI13, 1.5×10^5 VEX⁺ C9P14 cells were adoptively transferred per mouse; for PR8-GP33 and LM-GP33, 1.0×10^5 VEX⁺ C9P14 cells were adoptively transferred per mouse.

B. LCMV-CI13 viral load was measured by plaque assay on D15 p.i. with CI13 in liver, kidney and serum of non-transferred (NT) mice or mice receiving sgCtrl⁺ or sgFli1⁺ adoptively transferred C9P14 cells. Data pooled from 2 independent experiments.

- C. Weight curve for PR8-GP33 infected mice from NT, sgCtrl⁺ cell-transferred, or sgFli1⁺ cell-transferred groups. Dashed line represents the time of C9P14 adoptive transfer.
- D. PR8-GP33 viral RNA load in the lung of NT, sgCtrl⁺ or sgFli1⁺ C9P14 recipient mice. Dashed line indicates the limit of detection. Lung samples from naïve mice and spleen samples from PR8-GP33 infected mice were used as negative controls.
- E. Adjusted survival curve of LM-GP33 infected mice for NT, sgCtrl⁺ or sgFli1⁺ C9P14 recipient mice. Dashed line represents the time of C9P14 adoptive transfer.
- F. LM-GP33 bacteria load in spleen and liver of the surviving NT, sgCtrl⁺ or sgFli1⁺ C9P14 recipient mice on D7 p.i.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.001$ versus control (One-Way Anova analysis). Data are representative of 2 independent experiments (mean \pm s.e.m.) with at least 3 mice/group.

Figure 7. Loss of Fli1 in CD8 T cells results in more potent anti-tumor immunity.

- A. Experimental design. On D0, CD45.2⁺Rag2^{-/-} mice were inoculated with 1×10^5 B16-D^bgp33 cells. On D3 post tumor inoculation (p.t.), CD8 T cells were isolated from CD45.1⁺ C9P14 mice and activated. On D4 p.t., activated C9P14 cells were transduced with sgCtrl or sgFli1 RVs for 6-8 hours. On D5 p.t., sgRNA (VEX)⁺Cas9 (GFP)⁺P14 cells were purified by flow cytometry from sgCtrl or sgFli1 groups, and 1×10^6 purified VEX⁺ C9P14 cells were adoptively transferred into the tumor-bearing mice.
- B. Tumor volume curve for mice receiving NT, sgCtrl⁺ or sgFli1⁺ C9P14 cells.
- C. Tumor weight on D23 p.t. for mice receiving NT, sgCtrl⁺ or sgFli1⁺ C9P14 cells.
- D-E. Flow cytometry plots (D) and statistical analysis (E) of CD45.1⁺ sgRNA(VEX)⁺Cas9⁺P14 cells and Ly108⁻CD39⁺/Ly108⁺CD39⁻ C9P14 cells from tumor for sgCtrl or sgFli1 groups on D23 p.t.
- F-G. Flow cytometry plots (F) and statistical analysis (G) of CD45.1⁺ sgRNA⁺Cas9⁺ P14 cells and Ly108⁻CD39⁺/Ly108⁺CD39⁻ C9P14 cells from spleen for sgCtrl or sgFli1 groups at D23 p.t.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.001$ versus control (two-tailed Student's *t*-test and One-Way Anova analysis). Data are representative of 2 independent experiments (mean \pm s.e.m.) with at least 5 mice/group.

STAR★ Methods

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Mouse strains		
C57BL/6	Charles River	N/A
CD45.1 ⁺ C57BL/6	Charles River	N/A
CD4 ^{CRE}	The Jackson Lab	Stock No. 022071
TCR α^{-} ; P14 TCRV α 2V β 8	The Jackson Lab	Stock No. 37394-JAX
Rag2 ^{-/-} C57BL/6	The Jackson Lab	Stock No: 008449
LSL-Cas9-GFP	The Jackson Lab	Stock No: 026175
Constitutive-Cas9-GFP	The Jackson Lab	Stock No: 026179
Flow cytometry reagents		
Live/Dead Aqua Dye	Thermofisher	Cat# L34957
Live/Dead Zombie NIR Dye	BioLegend	Cat# 423106
Anti-Mouse KLRG1(2F1)	BD Biosciences	Cat# 561619, RRID:AB_10898017
Anti-Mouse CD127(A7R34)	BioLegend	Cat# 135016, RRID:AB_1937261
Anti-Mouse CD8(53-6.7)	BioLegend	Cat# 100742, RRID:AB_2563056
Anti-Mouse CD44(IM7)	BioLegend	Cat# 103059, RRID:AB_2571953
Anti-Mouse CD45.1(A20)	BioLegend	Cat# 110724, RRID:AB_493733; Cat# 110716, RRID:AB_313505
Anti-Mouse CD45.2(104)	BioLegend	Cat# 109828, RRID:AB_893350; Cat# 109823, RRID:AB_830788
Anti-Mouse Ly108(330-AJ)	BioLegend	Cat# 134608, RRID:AB_2188093; Cat# 134605, RRID:AB_1659258
Anti-Mouse Tim-3(RMT3-23)	BioLegend	Cat# 119721, RRID:AB_2616907
Anti-Mouse CD39(24DMS1)	Thermofisher	Cat# 46-0391-80, RRID:AB_10717513
Anti-Mouse PD-1(RMP1-30)	BioLegend	Cat# 109109, RRID:AB_572016
Anti-Mouse CD28	BioLegend	Cat# 644808, RRID:AB_1595479
Anti-Mouse CX3CR1	Thermofisher	Cat# 50-4875-80, RRID:AB_2574226
Anti-Mouse CXCR3	BioLegend	Cat# 652420, RRID:AB_2564285

Anti-Mouse TCF-1(S33-966)	BD Biosciences	Cat# 564217, RRID:AB_2687845
Anti-Mouse Gzmb (GB11)	Thermofisher	Cat# GRB17, RRID:AB_2536540
LCMV D ^b GP33 tetramer	NIH	Conjugated in house
Foxp3 Transcription Factor Staining Buffer Kit	Thermofisher	Cat# A25866A
Experimental Models		
LCMV Clone13 (CI13)	Rafi Ahmed	Grew up in house
LCMV Armstrong (Arm)	Rafi Ahmed	Grew up in house
<i>Listeria Monocytogenes</i> -D ^b GP33	Hao Shen	Grew up in house
<i>Influenza-PR8</i> -D ^b GP33	Richard J. Webby	Grew up at St. Jude Children's Hospital
B16-D ^b GP33	(Prévost-Blondel et al., 1998a)	Grew up in house
In vitro culture and retroviral transduction reagents		
Recombinant human IL-2	NIH	N/A
Anti-Mouse CD3(145-2C11)	BioLegend	Cat# 100302, RRID:AB_312667
Anti-Mouse CD28(37.51)	Thermofisher	Cat# 16-0281-82, RRID:AB_468921
EasySep™ Mouse CD8+ T Cell Isolation Kit	STEMCELL Technologies	Cat# 19853
RPMI-1640 medium	Corning/Mediatech	Cat# 10-040-CV
DMEM medium	Corning/Mediatech	Cat# 10-017-CV
HI Fetal Bovine Serum	Thermofisher	Cat# 26170-043
HEPES	Thermofisher	Cat# 15630080
Non-Essential Amino Acids	Thermofisher	Cat# 11140050
Penicillin-Streptomycin	Thermofisher	Cat# 15140122
β-mercaptoethanol	Sigma-Aldrich	Cat# M6250-500ML
Opti-MEM	Thermofisher	Cat# 31985088
Polybrene	Sigma-Aldrich	Cat# TR-1003-G
Lipofectamine™ 3000 Transfection Reagent	Thermofisher	Cat# L3000001
Molecular constructs		
Runx1 overexpression vector	Nancy A. Speck; Addgene	N/A; Addgene Cat#80157
Runx3 overexpression vector	In this paper	N/A

Fli1 overexpression vector	In this paper	N/A
Empty-VEX retroviral vector	(Kurachi et al. 2017)	N/A
Empty-mCherry retroviral vector	(Kurachi et al. 2017)	N/A
pSL21-VEX	In this paper	N/A
pSL21-mCherry	In this paper	N/A
LRG2.1	Addgene	Cat#108098
MSCV Retroviral Expression System	Takara Bio.	Cat#634401
BbsI	NEB	Cat#R0539L
Esp3I(BsmBI)	Thermofisher	Cat#ER0451
Phusion Flash High Fidelity PCR Master Mix with HF buffer	Thermofisher	Cat#F531L
Gibson Assembly Master Mix	NEB	Cat#E2611L
T4 DNA Polymerase	NEB	Cat#M0203L
DNA Polymerase I, Large (Klenow) Fragment	NEB	Cat#M0210L
T4 polynucleotide kinase	NEB	Cat#M0201L
Klenow Fragment	NEB	Cat#M0212L
PrimeSTAR HS DNA Polymerase	Takara Bio.	Cat#R040A
Quick T4 DNA Ligase	NEB	Cat#M2200
Antibodies for biochemical experiments		
Anti-Mouse Fli1	Abcam	Cat# ab15289
Guinea Pig anti-Rabbit IgG (Heavy & Light Chain) Antibody	Antibodies-online	Cat# ABIN101961
Anti-Mouse GAPDH	Cell Signaling Technology	Cat# 14C10
IRDye 800 CW Goat anti-Rabbit Antibody	Licor	#92632211
RNA-Sequencing Processing Reagents		
RNeasy Micro Kit	Qiagen	Cat# 74004
SMART-Seq® v4 Ultra® Low Input RNA Kit for Sequencing (24 rxn)	Takara Bio	Cat# 634889

Nextera XT DNA Library Preparation Kit	Illumina	Cat# FC-131-1024
Agencourt AMPure XP	Beckman	Cat# A63880
HSD5000 ScreenTape	Agilent	Cat# 5067-5592
HSD1000 ScreenTape	Agilent	Cat# 5067-5584
ATAC-Sequencing Processing Reagents		
IGEPAL-CA-630	Sigma-Aldrich	Cat# I8896
Tn5 Transposases	Illumina	Cat# FC-121-1030
MinElute PCR Purification Kit	Qiagen	Cat# 28004
NEBNext High-Fidelity 2x PCR Master Mix	New England Labs	Cat# M0541
CUT&RUN Processing Reagents		
Digitonin	Millipore	Cat# 300410-1GM
BioMag Plus Concanavalin A (10mL)	Bangs laboratories	Cat# BP531
Complete, EDTA-free Protease Inhibitor Cocktail	Sigma	Cat# 4693132001
Glycogen	Thermo	Cat# R0561
Proteinase K	Denville Scientific	Cat# CB3210-5
RNase A	Thermo	Cat# EN0531
Spermidine	Sigma	Cat# 85558-1G
NEB Next Ultra II DNA library prep kit	NEB	Cat# E7645L
Illumina Sequencing Reagents		
NEBNext Library Quant Kit for Illumina	NEB	Cat# E7630L
NextSeq 500/550 High Output Kit (75 cycles) v2.5 kit	Illumina	Cat# 20024906
NextSeq 500/550 High Output Kit (150 cycles) v2.5 kit	Illumina	Cat# 20024907
Software and Algorithms		

FlowJo v10.4.2	TreeStar	https://www.flowjo.com/solutions/flowjo/downloads
Prism Version 8	GraphPad Software	https://www.graphpad.com/scientific-software/prism/
IGV v2.4.16	The Broad Institute	https://software.broadinstitute.org/software/igv/download
Deseq2	(Love et al., 2014)	http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html
Great (v3.0)	(McLean et al., 2010)	http://great.stanford.edu/public/html/
GSEA (v3.0)	The Broad Institute	http://software.broadinstitute.org/gsea/index.jsp
ClusterProfiler	(Yu et al., 2012)	https://guangchuangyu.github.io/2016/01/go-analysis-using-clusterprofiler/
Homer (v4.6)	(Heinz et al., 2010)	http://homer.ucsd.edu/homer/download.html
Bowtie2 v2.3.4.1	(Langmead and Salzberg, 2012)	http://bowtie-bio.sourceforge.net/bowtie2/index.shtml
Picard v1.96	The Broad Institute	https://broadinstitute.github.io/picard/index.html
Samtools v1.1	(Li et al., 2009)	http://samtools.sourceforge.net
Bedtools v2.28.0	(Quinlan and Hall, 2010)	https://bedtools.readthedocs.io/en/latest/#
bedGraphToBigWig (UCSC)	UCSC Genome	http://hgdownload.soe.ucsc.edu/admin/exe/linux.x86_64/
MACS v2.1	(Zhang et al., 2008)	https://github.com/taoliu/MACS
HOMER v4	(Heinz et al., 2010)	http://homer.ucsd.edu/homer/
ChIPpeakAnno	(Zhu et al., 2010)	https://bioconductor.org/packages/release/bioc/html/ChIPpeakAnno.html
ComplexHeatmap	(Gu et al., 2016)	https://bioconductor.org/packages/release/bioc/html/ComplexHeatmap.html
Datasets		

Blacklist	ENCODE	https://sites.google.com/site/anshulkundaje/projects/blacklists
T _{EFF} gene signature	(Bengsch et al., 2018)	N/A
T _{EX} precursor gene signature	(Chen et al., 2019b)	GSE131535
sgCtrl vs sgFli1 RNA sequencing at D8 CI13 p.i.	In this paper	GSE149838
sgCtrl vs sgFli1 ATAC sequencing at D9 CI13 p.i.	In this paper	GSE149836
IgG vs Fli1-ab(ab15289) CUT&RUN Sequencing at D8 CI13 p.i.	In this paper	GSE149837

Experimental Procedures

Mice

CD4^{CRE}, LSL-Cas9-GFP and Constitutive-Cas9-GFP mice were purchased from Jackson Laboratory. LSL-Cas9-GFP mice were bred to CD4^{CRE} mice and TCR transgenic P14 C57BL/6 mice (TCR specific for LCMV D^bGP₃₃₋₄₁) and back crossed for more than 6 generations before use. Constitutive-Cas9-GFP mice were bred to TCR transgenic P14 C57BL/6 mice. Constitutive-Cas9-GFP mice for recipient use were bred in house. 6-8 week-old C57BL/6 Ly5.2CR (CD45.1) or C57BL/6 (CD45.2) mice were purchased from NCI. 5-7 week-old Rag2^{-/-} C57BL/6 mice were purchased from Jackson Laboratory. Both male and female mice were used. All mice were used in accordance with Institutional Animal Care and Use Committee guidelines for the University of Pennsylvania.

Experimental models

LCMV Infection: Mice were infected intraperitoneally (i.p.) with 2×10^5 plaque-forming units (PFU) LCMV Armstrong or intravenously (i.v.) with 4×10^6 PFU LCMV CI13. Plaque assay for LCMV-CI13 to detect viral load was processed as previously described (Pauken et al., 2016).

Listeria Monocytogenes (LM) infection: LM expressing D^bGP33(LM-gp33) concentration was measured by optical density (OD) after overnight culture in brain heart infusion (BHI) media (1 OD refers to 8×10^8 LM-gp33). Each recipient mouse was infected intravenously (i.v.) with 1×10^5 CFU LM-gp33. Adjusted survival was based on mice remaining above the mandatory Institutional Animal Care and Use Committee (IACUC) euthanasia cut off of 30% weight loss. LM-gp33 colony formation per unit calculation for bacteria load was calculated as previously described (Chen et al., 2017).

Influenza PR8 infection: Mice were infected intranasally (i.n.) with PR8 strain expressing D^bGP33 (PR8-gp33)

at a dose of 3.0 LD₅₀. Mice were anesthetized before i.n. infection. PR8 viral qPCR detection for viral RNA amount was calculated as previously described (Laidlaw et al., 2013).

Tumor transfer: B16F10 melanoma cells expressing D^bGP33 (B16F10-gp33, (Prévost-Blondel et al., 1998b)) were maintained at 37 °C in DMEM medium supplemented with 10% FBS, penicillin, streptomycin and L-glutamine. Tumor cells were injected subcutaneously into the flanks of Rag2^{-/-} mice at 1 x 10⁵ cells/recipient and of Cas9⁺ B6 mice at 2 x 10⁵ cells/recipient. Activated sgRNA⁺ C9P14 cells are sorted and transferred into recipient mice at a dose of 1 x 10⁶ cells/recipient (for Rag2^{-/-}) or 3 x 10⁶ cells/recipient (for Cas9⁺). Tumor size was measured using digital calipers every 2-3 days after inoculation.

Vector construction and sgRNA cloning

In this study, SpCas9 sgRNA was expressed using pSL21-VEX or pSL21-mCherry (U6-sgRNA-EFS-VEX or U6-sgRNA-EFS-mCherry, will be available through Addgene). To generate the pSL21-VEX or pSL21-mCherry, U6-sgRNA expression cassette was PCR cloned from LRG2.1 into a retroviral vector MSCV-Neo, followed by swapping the Neo selection marker with a VEX or mCherry fluorescence reporter. sgRNAs were cloned by annealing two DNA oligos and T4 DNA ligation into a Bbs1- digested pSL21-VEX or pSL21-mCherry vector. To improve U6 promoter transcription efficiency, an additional 5' G nucleotide was added to all sgRNA oligo designs that did not already start with a 5' G. Runx1 and Runx3 constructs are built on the MIGR or MSCV-mCherry constructs, empty MIGR or MSCV-mCherry are used as the controls for these vectors.

Cell culture and in vitro stimulation

CD8⁺ T cells were purified from spleens by negative selection using EasySep Mouse CD8⁺ T Cell Isolation Kit (STEMCELL Technologies) according to manufacturer's instructions. Cells were stimulated with 100 U/mL recombinant human IL-2, 1 µg/mL anti-mouse CD3ε, and 5 µg/mL anti-mouse CD28 in RPMI-1640 medium with 10% fetal bovine serum (FBS), 10 mM HEPES, 100 µM non-essential amino acids (NEAA), 50 U/mL penicillin, 50 µg/mL streptomycin, and 50 µM β-mercaptoethanol.

Retroviral vector (RV) experiments

RVs were produced in 293T cells with MSCV and pCL-Eco plasmids using Lipofectamine 3000. RV transduction was performed as described (Kurachi et al., 2017). Briefly, CD8⁺ T cells were purified from spleens of P14 mice using EasySepTM Mouse CD8⁺ T Cell Isolation Kit. After 18-24 hrs of *in vitro* stimulation, P14 cells were transduced with RV in the presence of polybrene (0.5 µg/ml) during spin infection (2,000 g for 60 min at 32°C) following incubation at 37°C for 6 hrs for single RV and sgRNA library, or 12 hrs for double RV. RV-transduced P14 cells were adoptively transferred into recipient mice that were infected 24-48 hrs prior to transfer.

Flow cytometry and sorting

For mouse experiments, tissues were processed, single cell suspensions obtained, and cells were stained as described (Wherry et al., 2003). Mouse cells were stained with LIVE/DEAD cell stain (Invitrogen) and antibodies targeting surface or intracellular proteins. Flow cytometry was performed with an LSR II. Cell sorting

experiments were performed with a BD-Aria sorter, with 70-micron nozzle and a 4°C circulating cool-down system for sequencing, western and TIDE assays.

For sorting RV⁺ cells optimized sorting in the transfer experiments, the BD Aria Sorter was set at 37°C and 100-micron nozzle, with a flow rate lower than 3.0. 3×10^6 Cells are concentrated in 300ul 10% complete RPMI with 100 U/mL recombinant human IL-2 during sorting. 37°C pre-warmed collection tubes with 10% complete RPMI (100 U/ml IL-2) are used. Sorted cells are washed by 37°C warm pure RPMI before transferring into recipients.

TIDE Assay

At least 1×10^4 Cas9⁺sgRNA⁺ T cell pellets were frozen down. Genomic DNA was isolated from these samples using QIAmp DNA Mini Kit. A TIDE PCR, using 2x Phusion Flash High-Fidelity PCR Master Mix and primers designed around the genome region of the sgRNA target part was run for each sample to extract the guide region from the genome DNA; the resulting products were then gel verified, PCR purified, and sent for Sanger sequencing.

Western Blot

2×10^5 T cells were sorted using FACS machine and the pellets were frozen down. Protein was from these samples was extracted and denatured by boiling at 95°C in 2X working loading sample buffer (1M Tris-HCl, 10% SDS, Glycerol, 10% Bromophenol blue). Lysate was run on a 10% SDS-PAGE gel and then transferred to a nitrocellulose membrane. Primary Fli1 (1:200) and GAPDH (1:1000) antibodies was staining over night, followed 1:5000 secondary antibody staining on the next day.

OpTICS screening

- **sgRNA candidate selection**

271 TFs that met the following criteria were selected 1) Among the top 50 differentially expressed across (Doering et al., 2012) and (Philip et al., 2017), 2) Among the top 10 differentially open TF motifs across Naïve, D8 Arm and D8 Cl13 in the previous described (Sen et al., 2016), 3) Involved in the top immune-regulatory families, such as IRF and STAT proteins. 120 TFs were manually chosen to be included in the TF library.

- **Library construction**

4-5 sgRNA were designed against individual DNA binding domains or other functional domains of each TF based on the domain sequence information retrieved from NCBI Conserved Domains Database. All of the sgRNA oligos, including positive and negative control sgRNAs, were synthesized by Integrated DNA Technologies (IDT) and pooled in equal molarity. The pooled sgRNA oligos were then amplified by PCR and cloned into BsmBI-digested SL21 vector using Gibson Assembly Kit. To verify the identity and relative representation of sgRNAs in the pooled plasmids, a deep-sequencing analysis was performed on a MiSeq

instrument. We confirmed that 100% of the designed sgRNAs were cloned in the SL21 vector and the abundance of >95% of individual sgRNA constructs was within 5-fold of the mean (data not shown).

- **Mouse Experimental Workflow**

On day 0, C9P14 cells were isolated from the spleens and lymph nodes of CD45.2⁺ C9P14 mice and processed to standard T cell activation protocol using anti-CD3/CD28 and IL-2; on the same day, naïve CD45.1⁺ recipient mice were infected by LCMV. On D1 p.i., activated C9P14 cells were transduced by RV-sgRNA library and incubated for 6 hours before washing out the RV supernatant. 18-24 hours later, the transduced sgRNA⁺Cas9⁺ cells were sorted. Then, 10% of the sgRNA⁺Cas9⁺ T cells were frozen down as a D2 baseline (T0 time point) control prior to any selection, while 90% of the cells are transfer to the infected recipients (maximum 1X10⁵ cells/recipient). On the T1 time point (D8 in the graph), sgRNA⁺Cas9⁺ CD45.2⁺ T cells were sorted out from multiple organs of the recipients.

- **Isolated library construction and MiSeq processing**

To quantify the sgRNA abundance of reference and end time points, the sgRNA cassette was PCR amplified from genomic DNA using high-fidelity polymerase. The PCR product was end-repaired by T4 DNA polymerase, DNA Polymerase I, Large (Klenow) Fragment, and T4 polynucleotide kinase. Next, a 3' A-overhang was then added to the ends of blunted DNA fragments with Klenow Fragment (3'-5' exo-). The DNA fragments were ligated to diversity-increased custom barcodes with Quick ligation kit. Illumina paired-end sequencing adaptors were attached to the barcoded ligated products through PCR reaction with high-fidelity polymerase. The final product was quantified by Bioanalyzer Agilent DNA 1000 and pooled together in equal molar ratio and pair-end sequenced by using MiSeq (Illumina) with MiSeq Reagent Kit V3 150-cycle (Illumina).

- **Data processing**

The sequencing data was de-multiplexed and trimmed to contain only the sgRNA sequence cassettes. The read count of each individual sgRNA was calculated with no mismatches and compared to the sequence of reference sgRNA as described previously (Shi et al., 2015). Data of each sample were normalized to the same read account. Waterfall plots (Figure 1B): For each gene, mean of the log₂ fold changes from multiple sgRNA was computed. Heatmap (Figure 1C): For each gene, mean of the log₁₀ fold changes from multiple sgRNA was computed. In the matrix of genes by conditions, quantile normalization was performed across conditions such that each condition has the same distribution of values. Genes were ordered by the mean value of each row. Histogram (Figure 1D): For each condition, the background (grey bars and the histogram) was plotted for sgRNAs of all the genes. The 5% and 95% intervals were extracted by using the 5th percentile and 95th percentile of background values. The red bars show the log folds change for sgRNAs for one gene (or the control)

RNA-Sequencing

- **Experiment workflow**

At D8 p.i. with CI13, CD8 T cells were isolated from spleens of infected recipients. VEX⁺GFP⁺ cells are sorted using FACS with >95% purity. RNA were isolated using the QIAGEN RNeasy Micro Kit with 2 x 10⁴ cell per sample. cDNA libraries were generated using SMARTSeq V4 Ultra Low kit. Libraries were quantified by qPCR using a KAPA Library Quant Kit (KAPA Biosystems). Normalized libraries were pooled, diluted to 1.8pg/ml loaded onto a TG NextSeq 500/550 Mid Output Kit v2 (150 cycles, 130M reads, Illumina) and paired-end sequencing was performed on a NextSeq 550 (Illumina). The estimated read depth per sample is 15M reads.

- **Data processing**

Raw FASTQ files from RNAseq paired-end sequencing were aligned to the GRCm38/mm10 reference genome using Kallisto (<https://pachterlab.github.io/kallisto/>). Sequencing reads were read in for 19357 genes and 8 samples. Genes with zero read count in more than three conditions were filtered out. 13628 genes remained after this step. Then, differential expression analysis was run using DESeq 2 package. The expression of 1440 genes were found to significantly differ between the two conditions at a BH corrected P-value < 0.05. GO enrichment analysis was performed using ClusterProfiler. The top 20 most enriched pathways are shown in the plot. GSEA was performed using the Broad Institute software (<https://www.broadinstitute.org/gsea/index.jsp>). Enrichment scores were calculated by comparing sgCtrl to sgFli1 groups. T_{EX} precursor gene signature was from(Chen et al., 2019b). T_{EFF} gene signature was from(Bengsch et al., 2018).

ATAC-Sequencing

- **Experimental Workflow**

ATACseq sample preparation was performed as described with minor modifications (Buenrostro et al., 2013). VEX⁺GFP⁺ cells were sorted using FACS with >95% purity. Sorted cells (2.5 x 10⁴) were washed twice in cold PBS and resuspended in 50μl of cold lysis buffer (10nM Tris-HCl, pH 7.4, 10mM NaCl, 3mM MgCl₂, 0.1% Tween). Lysates were centrifuge (750xg, 10min, 4°C) and nuclei were resuspended in 50μl of transposition reaction mix (TD buffer [25μl], Tn5 Transposase [2.5μl], nuclease-free water [22.5μl]; (Illumina)) and incubated for 30min at 37°C. Transposed DNA fragments were purified using a Qiagen Reaction MiniElute Kit, barcoded with NEXTERA dual indexes (Illumina) and amplified by PCR for 11 cycles using NEBNext High Fidelity 2x PCR Master Mix (New England Biolabs). PCR products were purified using a PCR Purification Kit (Qiagen) and amplified fragment sizes were verified on a 2200 TapeStation (Agilent Technologies) using High Sensitivity D1000 ScreenTapes (Agilent Technologies). Libraries were quantified by qPCR using a KAPA Library Quant Kit (KAPA Biosystems). Normalized libraries were pooled, diluted to 1.8pg/ml loaded onto a TG NextSeq 500/550 Mid Output Kit v2 (150 cycles,

130M reads, Illumina) and paired-end sequencing was performed on a NextSeq 550 (Illumina). Estimation read depth per sample is 10M reads.

- **Data processing**

Raw ATACseq FASTQ files from paired-end sequencing were processed using the script available at the following repository (https://github.com/wherrylab/jogiles_ATAC). Samples were aligned to the GRCm38/mm10 reference genome using Bowtie2. We used samtools to remove unmapped, unpaired, mitochondrial reads. ENCODE blacklist regions were also removed

(<https://sites.google.com/site/anshulkundaje/projects/blacklists>). PCR duplicates were removed using Picard. Peak calling was performed using MACS v2 (FDR q-value 0.01). For each experiment, we combined peaks of all samples to create a union peak list and merged overlapping peaks with BedTools *merge*. The number of reads in each peak was determined using BedTools *coverage*. Differentially accessible regions were identified following DESeq2 normalization using an FDR cut-off < 0.05 unless otherwise indicated. Motif enrichment was calculated using HOMER (default parameters) on peaks differentially accessible across sgCtrl group and sgFli1 group. Transcription binding site prediction analysis was performed using known motif discovery strategy.

CUT&RUN

- **Experimental Workflow**

CUT&RUN experiments were performed as previously described (Skene et al., 2018) with modifications. Briefly, 2×10^5 sorted cells were washed twice with 1 ml of cold wash buffer (20 mM HEPES-NaOH pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, and protease inhibitor cocktails from Sigma) in 1.5ml tubes. Cells were then resuspended in 1 ml of cold wash buffer and incubated with 10 μ l of BioMagPlus Concanavalin A (Bangs laboratories) by rotating at 4°C for 25 min to allow the cells to bind. Tubes were placed on a magnetic stand and liquid was removed after the solution turned clear. Primary antibody in 250 μ l of cold antibody buffer (20 mM HEPES-NaOH pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 2 mM EDTA, 0.1% digitonin, and protease inhibitor cocktails from Sigma) was added to the tubes and rotated at 4°C overnight. The next day, after washing cells once with 1 ml of cold wash buffer, protein A-MNase (pA-MN) in 250 μ l of cold digitonin buffer (20 mM HEPES-NaOH pH 7.5, 150 mM NaCl, 0.5 mM Spermidine, 0.1% digitonin, and protease inhibitor cocktails from Sigma) was added to the tube and rotate at 4°C for 1 h. To wash away unbound pA-MN, cells were washed twice with 1 ml of cold digitonin buffer, and then resuspended in 150 μ l of cold digitonin buffer. The tubes were placed on a pre-cooled metal block. To initiate pA-MN digestion, 3 μ l of 0.1 M CaCl_2 was mixed with cells in 150 μ l cold digitonin buffer by gently flicking the tubes 10 times. Tubes were immediately placed back in the metal block. After 30 min incubation, the digestion was stopped by adding 150 μ l of 2x stop buffer (340 mM NaCl, 20 mM EDTA, 4 mM EGTA, 0.02% Digitonin, 50

µg/ml RNase A, 50 µg/ml Glycogen, and 4 pg/ml yeast heterologous spike-in DNA). Target chromatin was released by incubating the tubes on a heat block at 37°C for 10 min. Supernatant was spun at 16,000 g for 5 min at 4°C and transferred to a new tube. Chromatin was incubated with 3 µl of 10% SDS and 2.5 µl of 20 mg/ml proteinase K at 70°C for 10 min, followed by phenol:chloroform:isoamyl alcohol extraction. Upper phase containing DNA was mixed with 20 µg of glycogen and incubated with 750 µl of cold 100% ethanol at -20°C overnight. DNA was precipitated by centrifugation at 20,000 g for 30 min at 4°C. DNA pellets was washed once by cold 100% ethanol, air-dried, and stored at -20°C for library preparation. Protein A-MNase (batch 6, use at 1:200) and yeast heterologous spike-in DNA were kindly provided by Dr. Steve Henikoff. The antibodies used were: Fli1, ab15289, used at 1:50 (abcam) and guinea pig anti-rabbit IgG, used at 1:100, ABIN101961 (antibodies-online).

CUT&RUN DNA library was prepared as previously described (Liu et al., 2018) with slight modifications. Briefly, all DNA precipitated from pA-MN digestion was used for library preparation using NEBNext Ultra II DNA Library Prep Kit (NEB). The adaptor was diluted to 1:25 for adaptor ligation. DNA was barcoded and amplified for 14 PCR cycle, and DNA library was cleaned up by AMPure XP beads (Liu et al., 2018). The library quality was checked with Qubit and bioanalyzer, and the quantity of the library was determined by qPCR using NEBNext Library Quant Kit for Illumina (NEB) according to manufacture's instruction. Eighteen barcoded libraries were pooled at equal molarity and sequenced in the NextSeq 550 platform with NextSeq 500/550 High Output Kit (75 cycles) v2.5 kit. Paired-end sequencing was carried out (42:6:0:42).

- **Data processing**

Paired-end reads were aligned to mm10 reference genome using Bowtie2 v2.3.4.1 with options suggested by Henikoff (Skene et al., 2018). Picard tools v1.96 was used to remove presumed PCR duplicates using the MarkDuplicates command. Bam files containing uniquely mapped reads were created using Samtools v1.1. For downstream analysis, biological replicates (3 per condition) were merged at this step. Bedtools v2.28.0 was used to generate fragment BED files with size 40bp-500bp. Blacklist regions, random chromosomes, and mitochondria were removed. Filtered BED files were used for downstream analysis. Read per million (RPM) normalized bigwig files were created using bedGraphToBigWig (UCSC) and were used to visualize binding signals. Peaks were called using MACS v2.1 using the broadPeak setting with p-value cutoff of 1e-8, -f BEDPE and IgG as controls. Genes proximal to peaks were annotated against the mm10 genome using annotatePeaks.pl from HOMER v4. Fli1 binding motifs were identified using findMotifsGenome.pl from HOMER v4. Venn diagram of comparison with ATAC-Seq peaks was plotted using Bioconductor package ChIPpeakAnno. Heatmap was generated using Bioconductor package ComplexHeatmap.

Statistical analysis

Statistical significance was calculated with unpaired two-tailed student's t-test or one-way ANOVA with Tukey's multiple comparisons test by Prism 7 (GraphPad Software). P values are reported in the figure legends.

Supplementary Figure Legends

Figure S1 High-efficiency gene editing using retroviral-transduced sgRNA in Cas9⁺ antigen specific CD8 T cells.

- A. Optimizing sgRNA backbone compared to the original sgRNA.
- B. Experimental design for *in vivo* gene editing test. At Day 0 (D0), CD8 T cells were isolated from CD45.1⁺ LSL-Cas9⁺CD4^{CRE+}P14 (C9P14) donor mice and activated with anti-CD3, anti-CD28 and IL-2; CD45.2⁺ WT recipient mice were infected with LCMV-Cl13. At D1 p.i., activated C9P14 cells were transduced with either Ctrl-sgRNA (sgCtrl) or *Pdcd1*-sgRNA (sgPdcd1). 6 hours after transduction, 5 X 10⁴ activated donor cells were adoptively transferred into infected recipient mice. C9P14 cells were then isolated, at the indicated times, from different organs of recipient mice for analysis.
- C. D2 *in vitro* transduction efficiency of activated C9P14 cells with sgRNA vector (mCherry). Gates are set based on the non-transduced control.
- D. Flow cytometry plots of Cas9(GFP)⁺sgRNA(mCherry)⁺ population in the spleen at D9 p.i. of sgCtrl group and sgPdcd1 group.
- E. Histogram of PD-1 expression and statistical analysis of PD-1⁺ population from the Cas9⁺sgRNA⁺ P14 cells in the PBMC (D7 p.i.), spleen (D9 p.i.) or liver (D9 p.i.).
- F. Sanger sequencing results for the *Pdcd1* locus from FACS sorted Cas9⁺sgRNA⁺ P14 cells from the sgCtrl group (pooled 5 mice) or the sgPdcd1 group (pooled 2 mice).
- G. Histogram of KLRG1 or CXCR3 expression and statistical analysis of KLRG1⁺ or CXCR3⁺ populations from Cas9⁺sgRNA⁺ P14 cells from the spleen (D8 p.i. of LCMV-Arm) between targeted-sgRNA and sgCtrl group.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.001$ versus control (two-tailed Student's *t*-test). Data are representative of 2 independent experiments (mean ± s.e.m.) with at least 3 mice/group.

Figure S2 Technical optimization of OptICS system.

A-B. Log₂ fold change (L2FC) of D8 p.i.(T1) to D2 baseline(T0) across different sgRNAs from spleen (A) or liver (B) under 3 conditions during LCMV-Arm infection. X axis represents different sgRNAs, y axis represents L2FC of D8 p.i.(T1) to D2 baseline(T0). Condition 1: No optimized sorting, average input coverage -- 100 cells/sgRNA, Cas9^{+/+} P14 donor. Condition 2: Optimized sorting (in Star Methods), average input coverage -- 400 cells/sgRNA, Cas9^{+/+} P14 donor. Condition 3: Optimized sorting, average input coverage -- 400 cells/sgRNA, Cas9^{+/-} P14 donor. Example target genes are highlighted with the indicated color.

- C. Rank correlation of targeted genes between 2 independent screenings of Cas9^{+/+} or Cas9^{+/-} donor P14 groups. The mean values of sgRNA L2FC from each targeted gene were calculated and ranked from the independent screenings. Pearson correlation of the rankings was calculated.
- D. Fold change enrichment of sgPdcd1 at D14 p.i. of LCMV-CI13 in the spleen. Data from the screening performed in Figure 1A-1C.
- E. Pearson correlation of different samples from the screening performed in Figure 1A-1C. Sample collection time (days p.i.), LCMV infection and organ of sorted Cas9⁺sgRNA⁺ cells are presented.

Figure S3 Genetic deletion of *Fli1* leads to a greater T cell expansion.

- A. TIDE assay results showing genome disruption efficiency of *Fli1* locus on the Cas9⁺*Fli1*-sgRNA (sgFli1)⁺ cells. Genome disruption was detected by sanger sequencing.
- B. Flow cytometry plots (gated on donor P14 cells) of Cas9 (GFP)⁺sgRNA(VEX)⁺ population on D2 after *in vitro* transduction; D8 and D15 p.i. of Arm from splenocytes from sgCtrl or 2 *Fli1*-sgRNA (sgFli1_290 and sgFli1_360) groups. 5 X 10⁴ activated donor cells were adoptively transferred into infected recipient mice on D1 p.i.
- C. Normalized Cas9⁺sgRNA⁺ cell numbers from PBMC, liver and lung from sgCtrl and the two sgFli1 groups at D8 and D15 p.i. of Arm. Cell numbers normalized to the sgCtrl group based on D2 *in vitro* transduction efficiency.
- D. Flow cytometry plots (gated on donor P14 cells) of Cas9⁺sgRNA⁺ P14 cells on D2 post *in vitro* transduction, D9 and D15 p.i. with CI13 (spleen) for sgCtrl and the two sgFli1 groups. 5 X 10⁴ activated donor P14 cells were adoptively transferred into the infected recipient mice on D1 p.i.
- E. Normalized Cas9⁺sgRNA⁺ cell numbers from PBMC, liver and lung from sgCtrl and the two sgFli1 groups at D9 and D15 p.i. of CI13. Cell number normalized to the sgCtrl group based on D2 *in vitro* transduction efficiency.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.001$ versus control (One-Way Anova analysis). Data are representative of 2-4 independent experiments (mean \pm s.e.m.) with at least 3 mice/group.

Figure S4 *Fli1* inhibits T_{EFF}-like differentiation on transcriptional and epigenetic levels.

- A-B. Statistical analysis of Ly108⁻CD39⁺ or TCF-1⁻Gzmb⁺ T_{EFF}-like cells and Ly108⁺CD39⁻ or TCF-1⁺Gzmb⁻ T_{EX} precursor cell numbers from spleen for sgCtrl and the two sgFli1 groups at D8 (A) and D15 (B) p.i. with CI13. Gated on Cas9(GFP)⁺ sgRNA (VEX)⁺ P14 cells.
- C. Flow cytometry plots and statistical analysis of cell number of CD45.2⁺VEX⁺ P14 for Empty-RV and

Fli1-OE-RV groups at D8 and D16 p.i. of CI13. At D0, CD45.2⁺ P14 cells were activated and CD45.1⁺ recipient mice were infected with CI13. On D1 p.i., activated P14 were transduced with either Empty-RV or Fli1-OE-RV for 6 hours. On D2 p.i., VEX⁺ P14 cells were sorted from each RV transduced group and 1X10⁵ cells were adoptively transferred into the infected recipients.

D-E. Flow cytometry plots and statistical analysis of Ly108⁻CD39⁺ or TCF-1⁻Gzmb⁺ T_{EFF}-like cells and Ly108⁺CD39⁻ or TCF-1⁺Gzmb⁻ T_{EX} precursor frequencies for Empty-RV and Fli1-OE-RV groups on D8 and D16 p.i. of CI13. Gated on VEX⁺ P14 cells.

F. Statistical analysis of CX3CR1⁺ and Tim-3⁺ frequencies for Empty-RV and Fli1-OE-RV groups on D8 and D16 p.i. of CI13. Gated on VEX⁺ P14 cells.

G. PCA plot for RNA-seq results of sgCtrl, sgFli1_290 and sgFli1_360 groups on D8 p.i. of CI13.

H. Overlap of all CUT&RUN Fli1 binding peaks with ATAC-seq detected peaks in sgCtrl and sgFli1 groups.

I. Histogram of all CUT&RUN peaks co-localized with the ATAC-seq peaks. Peaks co-localized with the ATAC-seq peaks are red; peaks not co-localized are blue.

J. CUT&RUN IgG or Fli1 binding signals for P14 cells on D9 p.i. and open chromatin region signals detected by ATAC-seq for sgCtrl, sgFli1_290 and sgFli1_360 groups in the *Tcf7* and *Id3* loci.

P*<0.05, *P*<0.01, ****P*<0.001 versus control (One-Way Anova analysis). Data are representative of 3 independent experiments (mean±s.e.m.) with at least 4 mice/group for A-D.

Figure S5. Fli1 coordinates with Runx1 and antagonizes Runx3 function.

A. Flow cytometry plots and statistical analysis of CD45.1⁺mCherry⁺ and Ly108⁻CD39⁺/Ly108⁺CD39⁻ P14 cell numbers for Empty-RV or Runx1-OE-RV on D2 *in vitro* and D7 p.i. At D0, CD45.1⁺ P14 cells were activated and CD45.2⁺ recipient mice were infected with CI13; At D1 p.i., activated P14 cells were transduced with Empty-RV or Runx1-OE-RV for 6 hours, and 1X10⁵ transduced P14 cells were adoptively transferred into infected recipient mice. Flow cytometry plots gated on the CD45.1⁺ P14 cells.

B. D2 *in vitro* transduction efficiency of sgCtrl-VEX+Empty-mCherry, sgCtrl-VEX+Runx1-mCherry, sgFli1_290-VEX+Empty-mCherry, and sgFli1_290-VEX+Runx1-mCherry C9P14 cells.

C. Statistical analysis of VEX⁺mCherry⁺ C9P14 cells and Ly108⁻CD39⁺/Ly108⁺CD39⁻ cell numbers from spleen for sgCtrl-VEX+Empty-mCherry, sgCtrl-VEX+Runx1-mCherry, sgFli1_290-VEX+Empty-mCherry, and sgFli1_290-VEX+Runx1-mCherry groups on D7 p.i. of CI13. Gated on Cas9(GFP)⁺CD45.2⁺ P14 cells.

D. D2 *in vitro* transduction efficiency of sgCtrl-mCherry+Empty-VEX, sgCtrl-mCherry+Runx3-VEX, sgFli1_290-mCherry+Empty-VEX, and sgFli1_290-mCherry+Runx3-VEX C9P14 cells.

E. Statistical analysis of VEX⁺mCherry⁺ C9P14 cells and Ly108⁻CD39⁺/Ly108⁺CD39⁻ cell numbers from spleen for sgCtrl-mCherry+Empty-VEX, sgCtrl-mCherry+Runx3-VEX, sgFli1_290-mCherry+Empty-VEX and sgFli1_290-mCherry+Runx3-VEX at D8 p.i. of CI13. Gated on Cas9⁺CD45.2⁺ P14 cells.

P*<0.05, *P*<0.01 versus control (two-tailed Student's *t*-test). Data are representative of 2 independent experiments (mean±s.e.m.) with at least 5 mice/group.

Figure S6. *Fli1*-deficiency results in CD8 T cell expansion during influenza virus or *Listeria monocytogenes* infection.

- A. Flow cytometry plots showing sgRNA(VEX)⁺ C9P14 cells in the lungs of influenza virus (PR8-GP33) infected mice, comparing non-transfer(NT), sgCtrl and sgFli1 groups at D8 p.i. "Recovered" was defined by complete weight recovery at D8 p.i.
- B. Correlation of sgRNA⁺ C9P14 cell numbers and weight ratio (D8 p.i./D2 p.i.) during the PR8-GP33 infection. In the "weight not recovered" group (weight ratio between 0.7 and 1.0), sgRNA⁺ C9P14 cell numbers were further compared.
- C. Flow cytometry plots and statistical analysis of sgRNA⁺ C9P14 cells in the spleens of PR8-GP33-infected recipient mice for non-transfer (NT), sgCtrl and sgFli1 groups at D8 p.i.
- D. Flow cytometry plots and statistical analysis of sgRNA⁺ C9P14 cells in the spleens of *Listeria monocytogenes*-infected recipients for non-transfer (NT), sgCtrl and sgFli1 groups at D7 p.i.

P*<0.05, *P*<0.01 versus control (two-tailed Student's *t*-test and One-Way Anova analysis). Data are representative of 2 independent experiments (mean±s.e.m.) with at least 6 mice/group.

Figure S7. Deleting *Fli1* in CD8 T cells leads to better tumor protection in an immune competent setting.

- A. Experimental design. On D0, CD45.2⁺Cas9⁺P14⁻ mice were inoculated with 2 x 10⁵ B16-D^bgp33 cells. On D3 post tumor inoculation (p.t.), CD8 T cells were isolated from CD45.2⁺ C9P14 donor mice and activated. The next day, activated C9P14 cells were transduced with sgCtrl or sgFli1 RV for 6 hours. On D5 p.t., sgRNA (VEX)⁺ P14 cells were sorted from sgCtrl or sgFli1 groups, and 3 x 10⁶ purified VEX⁺ C9P14 cells were adoptively transferred into tumor-bearing mice.
- B. Tumor volume curve of tumor-bearing mice from NT, sgCtrl⁺ and sgFli1⁺ C9P14 cell transferred groups.
- C. Tumor weight from NT, sgCtrl⁺ and sgFli1⁺ C9P14 transferred mice on D24 p.t.
- D-E. Flow cytometry plots (D) and statistical analysis (E) of sgRNA (VEX)⁺ C9P14 cells and Ly108⁻CD39⁺/Ly108⁺CD39⁻ populations from tumor for sgCtrl and sgFli1 groups on D24 p.t.

F-G. Statistical analysis of sgRNA⁺ C9P14 cells and Ly108⁻CD39⁺/Ly108⁺CD39⁻ populations from draining lymph node (dLN, F) and spleen (G) for sgCtrl and sgFli1 groups on D24 p.t.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.001$ versus control (two-tailed Student's t -test and One-Way Anova analysis). Data are representative of 3 independent experiments (mean \pm s.e.m.) with at least 6 mice/group.

Reference

- Alfei, F., Kanev, K., Hofmann, M., Wu, M., Ghoneim, H.E., Roelli, P., Utzschneider, D.T., Hösclin, von, M., Cullen, J.G., Fan, Y., et al. (2019). TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection. *Nature* 2017 545:7652 1.
- Alizadeh, D., Wong, R.A., Yang, X., Wang, D., Pecoraro, J.R., Kuo, C.-F., Aguilar, B., Qi, Y., Ann, D.K., Starr, R., et al. (2019). IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. *Cancer Immunol Res* 7, 759–772.
- Angelosanto, J.M., Blackburn, S.D., Crawford, A., and Wherry, E.J. (2012). Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. *J. Virol.* 86, 8161–8170.
- Badovinac, V.P., Haring, J.S., and Harty, J.T. (2007). Initial T Cell Receptor Transgenic Cell Precursor Frequency Dictates Critical Aspects of the CD8+ T Cell Response to Infection. *Immunity* 26, 827–841.
- Badovinac, V.P., Porter, B.B., and Harty, J.T. (2004). CD8 + T cell contraction is controlled by early inflammation. *Nature Immunology* 2006 7:12 5, 809–817.
- Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., Freeman, G.J., and Ahmed, R. (2006). Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* 2017 545:7652 439, 682–687.
- Bensch, B., Ohtani, T., Khan, O., Setty, M., Manne, S., O'Brien, S., Gherardini, P.F., Herati, R.S., Huang, A.C., Chang, K.-M., et al. (2018). Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells. *Immunity* 48, 1029–1045.e5.
- Blackburn, S.D., Shin, H., Freeman, G.J., and Wherry, E.J. (2008). Selective expansion of a subset of exhausted CD8 T cells by α PD-L1 blockade. *Pnas* 105, 15016–15021.
- Blattman, J.N., Wherry, E.J., Ha, S.-J., van der Most, R.G., and Ahmed, R. (2009). Impact of Epitope Escape on PD-1 Expression and CD8 T-Cell Exhaustion during Chronic Infection. *J. Virol.* 83, 4386–4394.
- Boulay, G., Sandoval, G.J., Riggi, N., Iyer, S., Buisson, R., Naigles, B., Awad, M.E., Rengarajan, S., Volorio, A., McBride, M.J., et al. (2017). Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain. *Cell* 171, 163–178.e19.
- Brown, C.E., and Mackall, C.L. (2019). CAR T cell therapy: inroads to response and resistance. *Nature Reviews Immunology* 2012 12:11 19, 73–74.

- Cai, X., Gao, L., Teng, L., Ge, J., Oo, Z.M., Kumar, A.R., Gilliland, D.G., Mason, P.J., Tan, K., and Speck, N.A. (2015). Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells. *Cell Stem Cell* *17*, 165–177.
- Cannarile, M.A., Lind, N.A., Rivera, R., Sheridan, A.D., Camfield, K.A., Wu, B.B., Cheung, K.P., Ding, Z., and Goldrath, A.W. (2006). Transcriptional regulator Id2 mediates CD8⁺ T cell immunity. *Nature Immunology* *7*:12 *7*, 1317–1325.
- Chen, J., López-Moyado, I.F., Seo, H., Lio, C.-W.J., Hempleman, L.J., Sekiya, T., Yoshimura, A., Scott-Browne, J.P., and Rao, A. (2019a). NR4A transcription factors limit CAR T cell function in solid tumours. *Nature* *2017* *545*:7652 *567*, 530–534.
- Chen, Z., Ji, Z., Ngiow, S.F., Manne, S., Cai, Z., Huang, A.C., Johnson, J., Staupe, R.P., Bengsch, B., Xu, C., et al. (2019b). TCF-1-Centered Transcriptional Network Drives an Effector versus Exhausted CD8 T Cell-Fate Decision. *Immunity* *51*, 840-855.
- Chen, Z., Stelekati, E., Kurachi, M., Yu, S., Cai, Z., Manne, S., Khan, O., Yang, X., and Wherry, E.J. (2017). miR-150 Regulates Memory CD8 T Cell Differentiation via c-Myb. *Cell Reports* *20*, 2584–2597.
- Cheng, C.K., Li, L., Cheng, S.H., Lau, K.M., Chan, N.P.H., Wong, R.S.M., Shing, M.M.K., Li, C.K., and Ng, M.H.L. (2008). Transcriptional repression of the RUNX3/AML2 gene by the t(8;21) and inv(16) fusion proteins in acute myeloid leukemia. *Blood* *112*, 3391–3402.
- Choo, A., Palladinetti, P., Passioura, T., Shen, S., Lock, R., Symonds, G., and Dolnikov, A. (2006). The Role of IRF1 and IRF2 Transcription Factors in Leukaemogenesis. *Cgt* *6*, 543–550.
- Cruz-Guilloty, F., Pipkin, M.E., Djuretic, I.M., Levanon, D., Lotem, J., Lichtenheld, M.G., Groner, Y., and Rao, A. (2009). Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. *Journal of Experimental Medicine* *206*, 51–59.
- Doering, T.A., Crawford, A., Angelosanto, J.M., Paley, M.A., Ziegler, C.G., and Wherry, E.J. (2012). Network Analysis Reveals Centrally Connected Genes and Pathways Involved in CD8⁺ T Cell Exhaustion versus Memory. *Immunity* *37*, 1130–1144.
- Dong, M.B., Wang, G., Chow, R.D., Ye, L., Zhu, L., Dai, X., Park, J.J., Kim, H.R., Errami, Y., Guzman, C.D., et al. (2019). Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. *Cell* *178*, 1189–1204.e23.

Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N.F., Goodall, C.P., Blair, T.C., Fox, B.A., McDermott, J.E., et al. (2018). Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. *Nature Communications* 2017 8 9, 1–13.

Fraietta, J.A., Lacey, S.F., Orlando, E.J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A.C., Wang, Y., O'Connor, R.S., Hwang, W.-T., et al. (2018). Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nature Medicine* 2018 24, 563–571.

Gangwal, K., Sankar, S., Hollenhorst, P.C., Kinsey, M., Haroldsen, S.C., Shah, A.A., Boucher, K.M., Watkins, W.S., Jorde, L.B., Graves, B.J., et al. (2008). Microsatellites as EWS/FLI response elements in Ewing's sarcoma. *Pnas* 105, 10149–10154.

Gerlach, C., Moseman, E.A., Loughhead, S.M., Alvarez, D., Zwijnenburg, A.J., Waanders, L., Garg, R., la Torre, de, J.C., and Andrian, von, U.H. (2016). The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis. *Immunity* 45, 1270–1284.

Grevet, J.D., Lan, X., Hamagami, N., Edwards, C.R., Sankaranarayanan, L., Ji, X., Bhardwaj, S.K., Face, C.J., Posocco, D.F., Abdulmalik, O., et al. (2018). Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells. *Science* 361, 285–290.

Grusdat, M., McIlwain, D.R., Xu, H.C., Pozdeev, V.I., Knievel, J., Crome, S.Q., Robert-Tissot, C., Dress, R.J., Pandya, A.A., Speiser, D.E., et al. (2014). IRF4 and BATF are critical for CD8 + T-cell function following infection with LCMV. *Cell Death and Differentiation* 2009 16:11 21, 1050–1060.

Gu, Z., Eils, R., and Schlesner, M. (2016). Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* 32, 2847–2849.

He, R., Hou, S., Liu, C., Zhang, A., Bai, Q., Han, M., Yang, Y., Wei, G., Shen, T., Yang, X., et al. (2016). Follicular CXCR5-expressing CD8⁺ T cells curtail chronic viral infection. *Nature* 2017 545:7652 537, 412–416.

Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X., Murre, C., Singh, H., and Glass, C.K. (2010). Simple Combinations of Lineage-Determining Transcription Factors Prime cis-Regulatory Elements Required for Macrophage and B Cell Identities. *Molecular Cell* 38, 576–589.

- Huang, A.C., Orlowski, R.J., Xu, X., Mick, R., George, S.M., Yan, P.K., Manne, S., Kraya, A.A., Wubbenhorst, B., Dorfman, L., et al. (2019). A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nature Medicine* 2018 25, 454–461.
- Huang, A.C., Postow, M.A., Orlowski, R.J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J.R., Wenz, B., et al. (2017). T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. *Nature* 2017 545:7652 545, 60–65.
- Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. (2016). Defining CD8⁺ T cells that provide the proliferative burst after PD-1 therapy. *Nature* 2017 545:7652 537, 417–421.
- Intlekofer, A.M., Takemoto, N., Wherry, E.J., Longworth, S.A., Northrup, J.T., Palanivel, V.R., Mullen, A.C., Gasink, C.R., Kaech, S.M., Miller, J.D., et al. (2005). Effector and memory CD8⁺ T cell fate coupled by T-bet and eomesodermin. *Nature Immunology* 2006 7:12 6, 1236–1244.
- Ishizuka, J.J., Manguso, R.T., Cheruiyot, C.K., Bi, K., Panda, A., Iracheta-Velvet, A., Miller, B.C., Du, P.P., Yates, K.B., Dubrot, J., et al. (2019). Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. *Nature* 2017 545:7652 565, 43–48.
- Joshi, N.S., Cui, W., Chandele, A., Lee, H.K., Urso, D.R., Hageman, J., Gapin, L., and Kaech, S.M. (2007). Inflammation Directs Memory Precursor and Short-Lived Effector CD8⁺ T Cell Fates via the Graded Expression of T-bet Transcription Factor. *Immunity* 27, 281–295.
- Kaech, S.M., and Cui, W. (2012). Transcriptional control of effector and memory CD8⁺ T cell differentiation. *Nature Reviews Immunology* 2012 12:11 12, 749–761.
- Kaelin, W.G. (2017). Common pitfalls in preclinical cancer target validation. *Nature Reviews Cancer* 2012 13:1 17, 441–450.
- Kallies, A., Xin, A., Belz, G.T., and Nutt, S.L. (2009). Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8⁺ T Cells and Memory Responses. *Immunity* 31, 283–295.
- Kao, C., Oestreich, K.J., Paley, M.A., Crawford, A., Angelosanto, J.M., Ali, M.-A.A., Intlekofer, A.M., Boss, J.M., Reiner, S.L., Weinmann, A.S., et al. (2011). Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8⁺ T cell responses during chronic infection. *Nature Immunology* 2006 7:12 12, 663–671.

Khan, O., Giles, J.R., McDonald, S., Manne, S., Ngiow, S.F., Patel, K.P., Werner, M.T., Huang, A.C., Alexander, K.A., Wu, J.E., et al. (2019). TOX transcriptionally and epigenetically programs CD8⁺ T cell exhaustion. *Nature* 2017 545:7652 1.

Koyama, S., Akbay, E.A., Li, Y.Y., Herter-Sprie, G.S., Buczkowski, K.A., Richards, W.G., Gandhi, L., Redig, A.J., Rodig, S.J., Asahina, H., et al. (2016). Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. *Nature Communications* 2017 8 7, 1–9.

Kruse, E.A., Loughran, S.J., Baldwin, T.M., Josefsson, E.C., Ellis, S., Watson, D.K., Nurden, P., Metcalf, D., Hilton, D.J., Alexander, W.S., et al. (2009). Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. *Pnas* 106, 13814–13819.

Kurachi, M., Barnitz, R.A., Yosef, N., Odorizzi, P.M., Dilorio, M.A., Lemieux, M.E., Yates, K., Godec, J., Klatt, M.G., Regev, A., et al. (2014). The transcription factor BATF operates as an essential differentiation checkpoint in early effector CD8⁺ T cells. *Nature Immunology* 2006 7:12 15, 373–383.

Kurachi, M., Kurachi, J., Chen, Z., Johnson, J., Khan, O., Bengsch, B., Stelekati, E., Attanasio, J., McLane, L.M., Tomura, M., et al. (2017). Optimized retroviral transduction of mouse T cells for *in vivo* assessment of gene function. *Nature Protocols* 2017 12:9 12, 1980–1998.

Kurachi, M., Ngiow, S.F., Kurachi, J., Chen, Z., and Wherry, E.J. (2019). Hidden Caveat of Inducible Cre Recombinase. *Immunity* 51, 591–592.

LaFleur, M.W., Nguyen, T.H., Coxe, M.A., Miller, B.C., Yates, K.B., Gillis, J.E., Sen, D.R., Gaudio, E.F., Abosy, A., Freeman, G.J., et al. (2019a). PTPN22 regulates the generation of exhausted CD8⁺ T cell subpopulations and restrains tumor immunity. *Nature Immunology* 2006 7:12 20, 1335–1347.

LaFleur, M.W., Nguyen, T.H., Coxe, M.A., Yates, K.B., Trombley, J.D., Weiss, S.A., Brown, F.D., Gillis, J.E., Coxe, D.J., Doench, J.G., et al. (2019b). A CRISPR-Cas9 delivery system for *in vivo* screening of genes in the immune system. *Nature Communications* 2017 8 10, 1668.

Laidlaw, B.J., Decman, V., Ali, M.-A.A., Abt, M.C., Wolf, A.I., Monticelli, L.A., Mozdanzowska, K., Angelosanto, J.M., Artis, D., Erikson, J., et al. (2013). Cooperativity between CD8⁺ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. *PLOS Pathogens* 9, e1003207.

Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nature Methods* 2017 14:3 9, 357–359.

- Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., 1000 Genome Project Data Processing Subgroup (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078–2079.
- Lin, W.-H.W., Nish, S.A., Yen, B., Chen, Y.-H., Adams, W.C., Kratchmarov, R., Rothman, N.J., Bhandoola, A., Xue, H.-H., and Reiner, S.L. (2016). CD8+ T Lymphocyte Self-Renewal during Effector Cell Determination. *Cell Reports* 17, 1773–1782.
- Lindsten, T., June, C.H., and Thompson, C.B. (1988). Multiple mechanisms regulate c-myc gene expression during normal T cell activation. *The EMBO Journal* 7, 2787–2794.
- Liu, N., Hargreaves, V.V., Zhu, Q., Kurland, J.V., Hong, J., Kim, W., Sher, F., Macias-Trevino, C., Rogers, J.M., Kurita, R., et al. (2018). Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch. *Cell* 173, 430–442.e17.
- Liu, X., Wang, Y., Lu, H., Li, J., Yan, X., Xiao, M., Hao, J., Alekseev, A., Khong, H., Chen, T., et al. (2019). Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. *Nature* 2017 545:7652 567, 525–529.
- Long, A.H., Haso, W.M., Shern, J.F., Wanhainen, K.M., Murgai, M., Ingaramo, M., Smith, J.P., Walker, A.J., Kohler, M.E., Venkateshwara, V.R., et al. (2015). 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. *Nature Medicine* 2018 21, 581–590.
- Lynn, R.C., Weber, E.W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019). c-Jun overexpression in CAR T cells induces exhaustion resistance. *Nature* 2017 545:7652 576, 293–300.
- Man, K., Gabriel, S.S., Liao, Y., Gloury, R., Preston, S., Henstridge, D.C., Pellegrini, M., Zehn, D., Berberich-Siebelt, F., Febbraio, M.A., et al. (2017). Transcription Factor IRF4 Promotes CD8+ T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection. *Immunity* 47, 1129–1141.e5.
- Man, K., Miasari, M., Shi, W., Xin, A., Henstridge, D.C., Preston, S., Pellegrini, M., Belz, G.T., Smyth, G.K., Febbraio, M.A., et al. (2013). The transcription factor IRF4 is essential for TCR affinity-mediated metabolic programming and clonal expansion of T cells. *Nature Immunology* 2006 7:12 14, 1155–1165.

Manguso, R.T., Pope, H.W., Zimmer, M.D., Brown, F.D., Yates, K.B., Miller, B.C., Collins, N.B., Bi, K., LaFleur, M.W., Juneja, V.R., et al. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. *Nature* 2017 545:7652 547, 413–418.

Martinez, G.J., Pereira, R.M., Äijö, T., Kim, E.Y., Marangoni, F., Pipkin, M.E., Togher, S., Heissmeyer, V., Zhang, Y.C., Crotty, S., et al. (2015). The Transcription Factor NFAT Promotes Exhaustion of Activated CD8+ T Cells. *Immunity* 42, 265–278.

Marzo, A.L., Klonowski, K.D., Le Bon, A., Borrow, P., Tough, D.F., and Lefrançois, L. (2005). Initial T cell frequency dictates memory CD8 + T cell lineage commitment. *Nature Immunology* 2006 7:12 6, 793–799.

McLane, L.M., Abdel-Hakeem, M.S., and Wherry, E.J. (2019). CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. *Annu. Rev. Immunol.* 37, 457–495.

McLane, L.M., Banerjee, P.P., Cosma, G.L., Makedonas, G., and Betts, M.R. (2013). Differential Localization of T-bet and Eomes in CD8 T Cell Memory Populations. *The Journal of Immunology* 190, 3207–3215.

Miller, B.C., Sen, D.R., Abosy, A.I., Bi, K., Virkud, Y.V., LaFleur, M.W., Yates, K.B., Lako, A., Felt, K., Naik, G.S., et al. (2019). Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade. *Nature Immunology* 2006 7:12 20, 326–336.

Milner, J.J., Toma, C., Yu, B., Zhang, K., Omilusik, K., Phan, A.T., Wang, D., Getzler, A.J., Nguyen, T., Crotty, S., et al. (2017). Runx3 programs CD8⁺ T cell residency in non-lymphoid tissues and tumours. *Nature* 2017 545:7652 552, 253–257.

Odorizzi, P.M., Pauken, K.E., Paley, M.A., Sharpe, A., and Wherry, E.J. (2015). Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8 +T cells. *Journal of Experimental Medicine* 212, 1125–1137.

Omilusik, K.D., Nadsombati, M.S., Shaw, L.A., Yu, B., Milner, J.J., and Goldrath, A.W. (2018). Sustained Id2 regulation of E proteins is required for terminal differentiation of effector CD8+ T cells. *Journal of Experimental Medicine* 215, 773–783.

Paley, M.A., Kroy, D.C., Odorizzi, P.M., Johnnidis, J.B., Dolfi, D.V., Barnett, B.E., Bikoff, E.K., Robertson, E.J., Lauer, G.M., Reiner, S.L., et al. (2012). Progenitor and Terminal Subsets of CD8+ T Cells Cooperate to Contain Chronic Viral Infection. *Science* 338, 1220–1225.

Pan, D., Kobayashi, A., Jiang, P., de Andrade, L.F., Tay, R.E., Luoma, A.M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018). A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. *Science* 359, 770–775.

Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D.R., Kurachi, M., et al. (2016). Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. *Science* 354, 1160–1165.

Pearce, E.L., Mullen, A.C., Martins, G.A., Krawczyk, C.M., Hutchins, A.S., Zediak, V.P., Banica, M., DiCioccio, C.B., Gross, D.A., Mao, C.-A., et al. (2003). Control of Effector CD8+ T Cell Function by the Transcription Factor Eomesodermin. *Science* 302, 1041–1043.

Pham, D., Moseley, C.E., Gao, M., Savic, D., Winstead, C.J., Sun, M., Kee, B.L., Myers, R.M., Weaver, C.T., and Hatton, R.D. (2019). Batf Pioneers the Reorganization of Chromatin in Developing Effector T Cells via Ets1-Dependent Recruitment of Ctcf. *Cell Reports* 29, 1203–1220.e1207.

Philip, M., Fairchild, L., Sun, L., Horste, E.L., Camara, S., Shakiba, M., Scott, A.C., Viale, A., Lauer, P., Merghoub, T., et al. (2017). Chromatin states define tumour-specific T cell dysfunction and reprogramming. *Nature* 2017 545:7652 545, 452–456.

Pimanda, J.E., Ottersbach, K., Knezevic, K., Kinston, S., Chan, W.Y.I., Wilson, N.K., Landry, J.-R., Wood, A.D., Kolb-Kokocinski, A., Green, A.R., et al. (2007). Gata2, Fli1, and Scl form a recursively wired gene-regulatory circuit during early hematopoietic development. *Pnas* 104, 17692–17697.

Platt, R.J., Chen, S., Zhou, Y., Yim, M.J., Swiech, L., Kempton, H.R., Dahlman, J.E., Parnas, O., Eisenhaure, T.M., Jovanovic, M., et al. (2014). CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling. *Cell* 159, 440–455.

Prévost-Blondel, A., Zimmermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F.M., and Pircher, H. (1998a). Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo. *The Journal of Immunology* 161, 2187–2194.

Prévost-Blondel, A., Zimmermann, C., Stemmer, C., Kulmburg, P., Rosenthal, F.M., and Pircher, H. (1998b). Tumor-Infiltrating Lymphocytes Exhibiting High Ex Vivo Cytolytic Activity Fail to Prevent Murine Melanoma Tumor Growth In Vivo. *The Journal of Immunology* 161, 2187–2194.

- Quigley, M., Pereyra, F., Nilsson, B., Porichis, F., Fonseca, C., Eichbaum, Q., Julg, B., Jesneck, J.L., Brosnahan, K., Imam, S., et al. (2010). Transcriptional analysis of HIV-specific CD8⁺ T cells shows that PD-1 inhibits T cell function by upregulating BATF. *Nature Medicine* 2018 16, 1147–1151.
- Quinlan, A.R., and Hall, I.M. (2010). BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* 26, 841–842.
- Ribas, A., and Wolchok, J.D. (2018). Cancer immunotherapy using checkpoint blockade. *Science* 359, 1350–1355.
- Riggi, N., Knoechel, B., Gillespie, S.M., Rheinbay, E., Boulay, G., Suvà, M.L., Rossetti, N.E., Boonseng, W.E., Oksuz, O., Cook, E.B., et al. (2014). EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma. *Cancer Cell* 26, 668–681.
- Roe, J.-S., Mercan, F., Rivera, K., Pappin, D.J., and Vakoc, C.R. (2015). BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. *Molecular Cell* 58, 1028–1039.
- Rutishauser, R.L., Martins, G.A., Kalachikov, S., Chandele, A., Parish, I.A., Meffre, E., Jacob, J., Calame, K., and Kaech, S.M. (2009). Transcriptional Repressor Blimp-1 Promotes CD8⁺ T Cell Terminal Differentiation and Represses the Acquisition of Central Memory T Cell Properties. *Immunity* 31, 296–308.
- Sade-Feldman, M., Yizhak, K., Bjorgaard, S.L., Ray, J.P., de Boer, C.G., Jenkins, R.W., Lieb, D.J., Chen, J.H., Frederick, D.T., Barzily-Rokni, M., et al. (2018). Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. *Cell* 175, 998–1013.e20.
- Scott, A.C., Dündar, F., Zumbo, P., Chandran, S.S., Klebanoff, C.A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S.J., et al. (2019). TOX is a critical regulator of tumour-specific T cell differentiation. *Nature* 2017 545:7652.
- Sen, D.R., Kaminski, J., Barnitz, R.A., Kurachi, M., Gerdemann, U., Yates, K.B., Tsao, H.-W., Godec, J., LaFleur, M.W., Brown, F.D., et al. (2016). The epigenetic landscape of T cell exhaustion. *Science* 354, 1165–1169.
- Seo, H., Chen, J., González-Avalos, E., Samaniego-Castruita, D., Das, A., Wang, Y.H., López-Moyado, I.F., Georges, R.O., Zhang, W., Onodera, A., et al. (2019). TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8⁺ T cell exhaustion. *Proc. Natl. Acad. Sci. U.S.A.* 116, 12410–12415.

- Shan, Q., Zeng, Z., Xing, S., Li, F., Hartwig, S.M., Gullicksrud, J.A., Kurup, S.P., Van Braeckel-Budimir, N., Su, Y., Martin, M.D., et al. (2017). The transcription factor Runx3 guards cytotoxic CD8 + effector T cells against deviation towards follicular helper T cell lineage. *Nature Immunology* 2006 7:12 18, 931–939.
- Shang, W., Jiang, Y., Boettcher, M., Ding, K., Mollenauer, M., Liu, Z., Wen, X., Liu, C., Hao, P., Zhao, S., et al. (2018). Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation. *Pnas* 115, E4051–E4060.
- Shi, J., Wang, E., Milazzo, J.P., Wang, Z., Kinney, J.B., and Vakoc, C.R. (2015). Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. *Nature Biotechnology* 2015 33:6 33, 661–667.
- Shifrut, E., Carnevale, J., Tobin, V., Roth, T.L., Woo, J.M., Bui, C.T., Li, P.J., Diolaiti, M.E., Ashworth, A., and Marson, A. (2018). Genome-wide CRISPR Screens in Primary Human T Cells Reveal Key Regulators of Immune Function. *Cell* 175, 1958–1971.e15.
- Shin, H., Blackburn, S.D., Intlekofer, A.M., Kao, C., Angelosanto, J.M., Reiner, S.L., and Wherry, E.J. (2009). A Role for the Transcriptional Repressor Blimp-1 in CD8+ T Cell Exhaustion during Chronic Viral Infection. *Immunity* 31, 309–320.
- Simoni, Y., Becht, E., Fehlings, M., Loh, C.Y., Koo, S.-L., Teng, K.W.W., Yeong, J.P.S., Nahar, R., Zhang, T., Kared, H., et al. (2018). Bystander CD8 + T cells are abundant and phenotypically distinct in human tumour infiltrates. *Nature* 2017 545:7652 557, 575–579.
- Singer, M., Wang, C., Cong, L., Marjanovic, N.D., Kowalczyk, M.S., Zhang, H., Nyman, J., Sakuishi, K., Kurtulus, S., Gennert, D., et al. (2016). A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells. *Cell* 166, 1500–1511.e1509.
- Skene, P.J., Elife, S.H., 2017 An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites. *Cdn.Elifesciences.org*
- .
- Skene, P.J., Henikoff, J.G., and Henikoff, S. (2018). Targeted in situ genome-wide profiling with high efficiency for low cell numbers. *Nature Protocols* 2017 12:9 13, 1006–1019.
- Sommermeier, D., Hudecek, M., Kosasih, P.L., Gogishvili, T., Maloney, D.G., Turtle, C.J., and Riddell, S.R. (2016). Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. *Leukemia* 30, 492–500.

- Stadtmauer, E.A., Fraietta, J.A., Davis, M.M., Cohen, A.D., Weber, K.L., Lancaster, E., Mangan, P.A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020). CRISPR-engineered T cells in patients with refractory cancer. *Science* eaba7365.
- Sullivan, B.M., Juedes, A., Szabo, S.J., Herrath, von, M., and Glimcher, L.H. (2003). Antigen-driven effector CD8 T cell function regulated by T-bet. *Pnas* *100*, 15818–15823.
- Sun, C., Mezzadra, R., and Schumacher, T.N. (2018). Regulation and Function of the PD-L1 Checkpoint. *Immunity* *48*, 434–452.
- Tiemessen, M.M., Baert, M.R.M., Kok, L., van Eggermond, M.C.J.A., van den Elsen, P.J., Arens, R., and Staal, F.J.T. (2014). T Cell Factor 1 Represses CD8+ Effector T Cell Formation and Function. *The Journal of Immunology* *193*, 5480–5487.
- Tijssen, M.R., Cvejic, A., Joshi, A., Hannah, R.L., Ferreira, R., Forrai, A., Bellissimo, D.C., Oram, S.H., Smethurst, P.A., Wilson, N.K., et al. (2011). Genome-wide Analysis of Simultaneous GATA1/2, RUNX1, FLI1, and SCL Binding in Megakaryocytes Identifies Hematopoietic Regulators. *Developmental Cell* *20*, 597–609.
- Tinoco, R., Alcalde, V., Yang, Y., Sauer, K., and Zuniga, E.I. (2009). Cell-Intrinsic Transforming Growth Factor- β Signaling Mediates Virus-Specific CD8+ T Cell Deletion and Viral Persistence In Vivo. *Immunity* *31*, 145–157.
- Topalian, S.L., Drake, C.G., and Pardoll, D.M. (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell* *27*, 450–461.
- Uehata, T., Iwasaki, H., Vandenbon, A., Matsushita, K., Hernandez-Cuellar, E., Kuniyoshi, K., Satoh, T., Mino, T., Suzuki, Y., Standley, D.M., et al. (2013). Malt1-Induced Cleavage of Regnase-1 in CD4+ Helper T Cells Regulates Immune Activation. *Cell* *153*, 1036–1049.
- Utzschneider, D.T., Charmoy, M., Chennupati, V., Pousse, L., Ferreira, D.P., Calderon-Copete, S., Danilo, M., Alfei, F., Hofmann, M., Wieland, D., et al. (2016). T Cell Factor 1-Expressing Memory-like CD8+ T Cells Sustain the Immune Response to Chronic Viral Infections. *Immunity* *45*, 415–427.
- Wang, D., Diao, H., Getzler, A.J., Rogal, W., Frederick, M.A., Milner, J., Yu, B., Crotty, S., Goldrath, A.W., and Pipkin, M.E. (2018). The Transcription Factor Runx3 Establishes Chromatin Accessibility of cis-Regulatory Landscapes that Drive Memory Cytotoxic T Lymphocyte Formation. *Immunity* *48*, 659–674.e6.

- Wang, G., Chow, R.D., Bai, Z., Zhu, L., Errami, Y., Dai, X., Dong, M.B., Ye, L., Zhang, X., Renauer, P.A., et al. (2019). Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. *Nature Immunology* 2006 7:12 168, 707.
- Wang, R., Dillon, C.P., Shi, L.Z., Milasta, S., Carter, R., Finkelstein, D., McCormick, L.L., Fitzgerald, P., Chi, H., Munger, J., et al. (2011). The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation. *Immunity* 35, 871–882.
- Wei, J., Long, L., Zheng, W., Dhungana, Y., Lim, S.A., Guy, C., Wang, Y., Wang, Y.-D., Qian, C., Xu, B., et al. (2019). Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. *Nature* 2017 545:7652 576, 471–476.
- Wei, S.C., Duffy, C.R., and Allison, J.P. (2018). Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. *Cancer Discov* 8, 1069–1086.
- Wherry, E.J., and Kurachi, M. (2015). Molecular and cellular insights into T cell exhaustion. *Nature Reviews Immunology* 2012 12:11 15, 486–499.
- Wherry, E.J., Blattman, J.N., and Ahmed, R. (2005). Low CD8 T-cell proliferative potential and high viral load limit the effectiveness of therapeutic vaccination. *J. Virol.* 79, 8960–8968.
- Wherry, E.J., Ha, S.-J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J.N., Barber, D.L., and Ahmed, R. (2007). Molecular Signature of CD8⁺ T Cell Exhaustion during Chronic Viral Infection. *Immunity* 27, 670–684.
- Wherry, E.J., Teichgräber, V., Becker, T.C., Masopust, D., Kaech, S.M., Antia, R., Andrian, von, U.H., and Ahmed, R. (2003). Lineage relationship and protective immunity of memory CD8 T cell subsets. *Nature Immunology* 2006 7:12 4, 225–234.
- Wu, T., Ji, Y., Moseman, E.A., Xu, H.C., Manghani, M., Kirby, M., Anderson, S.M., Handon, R., Kenyon, E., Elkahloun, A., et al. (2016). The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. *Science Immunology* 1, eaai8593–eaai8593.
- Xin, A., Masson, F., Liao, Y., Preston, S., Guan, T., Gloury, R., Olshansky, M., Lin, J.-X., Li, P., Speed, T.P., et al. (2016). A molecular threshold for effector CD8⁺ T cell differentiation controlled by transcription factors Blimp-1 and T-bet. *Nature Immunology* 2006 7:12 17, 422–432.

- Xing, S., Li, F., Zeng, Z., Zhao, Y., Yu, S., Shan, Q., Li, Y., Phillips, F.C., Maina, P.K., Qi, H.H., et al. (2016). Tcf1 and Lef1 transcription factors establish CD8 + T cell identity through intrinsic HDAC activity. *Nature Immunology* 2006 7:12 17, 695–703.
- Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019). CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia. *N. Engl. J. Med.* 381, 1240–1247.
- Yang, C.Y., Best, J.A., Knell, J., Yang, E., Sheridan, A.D., Jesionek, A.K., Li, H.S., Rivera, R.R., Lind, K.C., D'Cruz, L.M., et al. (2011). The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8⁺ T cell subsets. *Nature Immunology* 2006 7:12 12, 1221–1229.
- Yao, C., Sun, H.-W., Lacey, N.E., Ji, Y., Moseman, E.A., Shih, H.-Y., Heuston, E.F., Kirby, M., Anderson, S., Cheng, J., et al. (2019). Single-cell RNA-seq reveals TOX as a key regulator of CD8⁺ T cell persistence in chronic infection. *Nature Immunology* 2006 7:12 20, 890–901.
- Ye, L., Park, J.J., Dong, M.B., Yang, Q., Chow, R.D., Peng, L., Du, Y., Guo, J., Dai, X., Wang, G., et al. (2019). In vivo CRISPR screening in CD8 T cells with AAV– Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. *Nature Biotechnology* 2015 33:6 39, 1–12.
- Yu, G., Wang, L.-G., Han, Y., and He, Q.-Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. *Omics* 16, 284–287.
- Zander, R., Schauder, D., Xin, G., Nguyen, C., Wu, X., Zajac, A., and Cui, W. (2019). CD4⁺ T Cell Help Is Required for the Formation of a Cytolytic CD8⁺ T Cell Subset that Protects against Chronic Infection and Cancer. *Immunity*.
- Zhang, Y., Liu, T., Meyer, C.A., Eeckhoute, J., Johnson, D.S., Bernstein, B.E., Nusbaum, C., Myers, R.M., Brown, M., Li, W., et al. (2008). Model-based Analysis of ChIP-Seq (MACS). 9, 1–9.
- Zhou, X., Yu, S., Zhao, D.-M., Harty, J.T., Badovinac, V.P., and Xue, H.-H. (2010). Differentiation and Persistence of Memory CD8⁺ T Cells Depend on T Cell Factor 1. *Immunity* 33, 229–240.
- Zhu, L.J., Gazin, C., Lawson, N.D., Pagès, H., Lin, S.M., Lapointe, D.S., and Green, M.R. (2010). ChIPpeakAnno: a Bioconductor package to annotate ChIP-seq and ChIP-chip data. *BMC Bioinformatics* 11, 1–10.




Figure 1





Figure 2








Figure 4


A




B




C




D



E



F



G




Figure 5




Figure 6




Figure 7